Patent Grant
11311340
The present technology is related to perivascular neuromodulation. In particular, various embodiments of the present technology are related to methods and systems for informed decision-making regarding whether to deliver neuromodulation therapy to various regions of a target blood vessel.
The sympathetic nervous system (SNS) is a primarily involuntary bodily control system typically associated with stress responses. Fibers of the SNS extend through tissue in almost every organ system of the human body and can affect characteristics such as pupil diameter, gut motility, and urinary output. Such regulation can have adaptive utility in maintaining homeostasis or in preparing the body for rapid response to environmental factors. Chronic activation of the SNS, however, is a common maladaptive response that can drive the progression of many disease states. Excessive activation of the renal SNS in particular has been identified experimentally and in humans as a likely contributor to the complex pathophysiology of hypertension, states of volume overload (e.g., heart failure), and progressive renal disease.
Sympathetic nerves of the kidneys terminate in the renal blood vessels, the juxtaglomerular apparatus, and the renal tubules, among other structures. Stimulation of the renal sympathetic nerves can cause, for example, increased renin release, increased sodium reabsorption, and reduced renal blood flow. These and other neural-regulated components of renal function are considerably stimulated in disease states characterized by heightened sympathetic tone. For example, reduced renal blood flow and glomerular filtration rate as a result of renal sympathetic efferent stimulation is likely a cornerstone of the loss of renal function in cardio-renal syndrome, (i.e., renal dysfunction as a progressive complication of chronic heart failure). Pharmacologic strategies to thwart the consequences of renal sympathetic stimulation include centrally-acting sympatholytic drugs, beta blockers (e.g., to reduce renin release), angiotensin-converting enzyme inhibitors and receptor blockers (e.g., to block the action of angiotensin II and aldosterone activation consequent to renin release), and diuretics (e.g., to counter the renal sympathetic mediated sodium and water retention). These pharmacologic strategies, however, have significant limitations including limited efficacy, compliance issues, side effects, and others.
Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present technology. For ease of reference, throughout this disclosure identical reference numbers may be used to identify identical or at least generally similar or analogous components or features.
Methods and systems in accordance with embodiments of the present technology can be configured to detect hemodynamic parameters of a patient's blood vessel, generate one or more models of the vessel, and analyze region(s) of the vessel to inform decision-making regarding potential regions for delivering neuromodulation therapy. Regions of the vessel may be identified for delivering therapy (e.g., target regions) while other regions may be identified as unsuitable for the therapy (e.g., avoidance regions). Specific details of several embodiments of the present technology are described herein with reference to
It should be noted that other embodiments in addition to those disclosed herein are within the scope of the present technology. Further, embodiments of the present technology can have different configurations, components, and/or procedures than those shown or described herein. Moreover, a person of ordinary skill in the art will understand that embodiments of the present technology can have configurations, components, and/or procedures in addition to those shown or described herein and that these and other embodiments can be without several of the configurations, components, and/or procedures shown or described herein without deviating from the present technology.
As used herein, the terms “distal” and “proximal” define a position or direction with respect to a clinician or a clinician's control device (e.g., a handle of a neuromodulation catheter). The terms, “distal” and “distally” refer to a position distant from or in a direction away from a clinician or a clinician's control device along the length of device. The terms “proximal” and “proximally” refer to a position near or in a direction toward a clinician or a clinician's control device along the length of device. The headings provided herein are for convenience only and should not be construed as limiting the subject matter disclosed.
Renal perivascular neuromodulation therapy aims to modulate the autonomic nervous system, specifically the SNS, by modulating or destroying renal efferent sympathetic nerves and afferent renal sensory nerves. However, delivering neuromodulation therapy in a vessel at a location having a local flow abnormality and/or a region of secondary flow increases a risk that a patient could experience an unwanted event in response to therapy. Local flow abnormalities and/or regions of secondary flow are not visible with conventional methods of vascular imaging, such as fluoroscopy. Therefore, the patient can benefit from methods and systems configured to display or otherwise inform a user (e.g., a clinician) of locations in the target blood vessel having local flow abnormalities and/or regions of secondary flow. In this way, the clinician can reduce the risk of an unwanted event by avoiding delivering neuromodulation therapy at these locations. The present technology includes several embodiments of methods and systems for avoiding delivering neuromodulation therapy to locations in the vessel having local flow abnormalities and/or regions of secondary flow. These methods and systems are configured to provide visual, audible, and/or tactile feedback to guide positioning of a neuromodulation catheter 210 at one or more suitable therapeutic locations in the patient's vessel.
In addition to receiving the three-dimensional imaging data at the processor, the method 100 includes receiving hemodynamic data regarding the blood vessel sensors (block 120). For example, the received hemodynamic data can be measurement of blood pressure, blood flow, blood impedance, viscosity of the patient's blood, other hemodynamic parameters, and/or combinations thereof. The received hemodynamic data can be based on measurements taken inside the vessel, outside the vessel, outside the patient's body, and/or a combination thereof. Blood viscosity can be assumed or measured. For example, blood viscosity is assumed to be 3×10−3 to 4×10−3 pascal-seconds (e.g., similar to water).
The blood pressure data, blood flow data, blood impedance data, and/or a combination thereof can be measured by one or more sensors, such as a sensor coupled to a neuromodulation catheter positioned in the target blood vessel in accordance with the present technology. In some embodiments, the method 100 includes coupling a sensor to the patient to detect and record data corresponding to one or more hemodynamic parameters either before or during an intravascular treatment. The sensor can be an external device that is coupled to the patient, for example, positioned near the patient's vessel. For example, the sensor can be an external pressure cuff, a Doppler ultrasound flow meter, a magnetic resonance imaging (MRI) machine, and/or combinations thereof. The sensor can alternatively be an internal device positioned within the patient, such as delivered transluminally into the patient's vessel. For example, the sensor can be coupled to a neuromodulation catheter 210 that can be delivered transluminally into the vessel. The transluminally delivered neuromodulation catheter can be positioned within a portion of the patient's vessel having laminar flow, and/or otherwise positioned to perform measurements of one or more hemodynamic parameters. The sensor can include, for example, a blood flow sensor, a blood pressure sensor, a blood impedance sensor, and/or a combination thereof. For example, the sensor can be a combination blood pressure-blood flow sensor carried by a guidewire (e.g., the blood pressure and blood flow sensor(s) can be the same sensor or different sensors located on the same guidewire) such as a fractional flow reserve (FFR) guidewire. In some embodiments, the combination guidewire also includes a transducer. In some embodiments, the method 100 can include coupling more than one sensor to the patient.
Several embodiments of the method 100 include measuring blood flow, blood pressure, and/or blood impedance in a main portion of the vessel (e.g., renal artery) and/or a branch of the main artery (e.g., anterior and/or posterior branch of renal artery). The measurements can be performed in a portion of the main vessel, or branch thereof, having stable (e.g., laminar) flow, a portion having unstable (e.g., turbulent, varied, secondary) flow, and/or a combination thereof.
After receiving the hemodynamic data, the method 100 continues by generating a computational fluid dynamics (CFD) model or representation of the target vessel based at least in part on the three-dimensional imaging data of the vessel (block 110) and the hemodynamic data (block 120). Using equations, algorithms, and various statistical methods, information regarding the three-dimensional imaging data of the vessel (e.g., vessel geometry) and hemodynamic data (e.g., blood pressure, blood flow, blood impedance, and/or blood viscosity) can be used to generate the CFD model of the vessel. The CFD model can be generated using a CFD workflow or other suitable methods for generating the CFD representation. The CFD workflow begins by fabricating a volumetric mesh to align with certain features of the vessel (e.g., geometry) represented by the three-dimensional imaging data. The hemodynamic data (e.g., blood flow data and/or blood pressure data) can be used to form one or more boundary conditions of the CFD simulation (e.g., the inlet) in the CFD workflow. The CFD workflow can generate a flow field and, if more than one CFD model is generated (e.g., different CFD models can be generated for certain portion of the vessel), the CFD models can be coupled (e.g., at the outlets) such that blood flow/blood pressure relationships can be computed. In some embodiments, the blood pressure data can be a proximal boundary condition and each outlet (e.g., distal boundary) can be coupled to a zero-dimensional representation of blood impedance, resistance, and compliance/capacitance of the patient's circulation distal to the boundaries. The CFD model can be displayed using one resolution in an image or multiple resolutions in a single representation. For example, a first portion of the CFD model can have a lower resolution compared to a second portion. Use of the lower resolution in the first portion is expected to reduce duration of certain computing parameters such that the CFD model having at least two resolutions can be generated faster than a CFD model having the resolution of the second portion displayed across the CFD model. In some embodiments, the CFD model can be validated using suitable validation methodologies (e.g., invasively measured values).
The user (e.g., clinician) and/or a computer can form certain assumptions about one or more features of the vessel physiology and hemodynamics or other information input into the CFD model. For example, an assumption can be that blood behaves as an incompressible fluid and/or a region of the vessel (e.g., segmented region) has rigid walls. In some embodiments, one or more hemodynamic parameters can be derived from empirical data, conglomerate data, and/or a combination thereof. In these embodiments, the CFD model of the vessel can be generated, in part, by applying one or more hemodynamic parameters derived from empirical data or conglomerate data to the CFD workflow. Empirical data can be obtained from a population database generated by the user or another party. The population database can include blood pressure data and/or blood flow data, each of which can be generalized. For example, generalized blood pressure can be 120/80 mmHg and generalized blood flow can be 500 ml/min. In additional embodiments, the CFD representation can include sample waveforms (e.g., measured, calculated, or standard) using computational methods such as ensemble averaging.
The CFD model is expected to aid in characterization and display of conventionally difficult to measure physiological and pathological parameters throughout the vessel targeted for perivascular denervation. CFD models are expected to quickly and accurately provide information regarding the vessel using anatomically accurate geometry and hemodynamically accurate inputs of the vessel. Iterative processing of CFD models can achieve convergence regarding physiological and pathological aspects of the modeled vessel(s). Measuring vessel wall shear stress (“WSS”) is difficult and invasive without CFD models which can map spatial distribution of WSS, one of several physiological features that may be desirable to avoid when delivering neuromodulation therapy.
Based on the CFD model generated by the processor (block 130), the method 100 can continue by identifying, with the processor, target regions and/or avoidance regions of the vessel for delivering neuromodulation therapy (block 140). Locations of avoidance regions can be identified on the CFD model by the processor using equations, algorithms, various statistical methods, and/or analysis of the patient's anatomical features, by user observation, and/or by a combination thereof. The avoidance regions can be one or more regions of the vessel having a local flow abnormality, a physiologic feature, and/or a pathologic feature (e.g., diseases) (collectively “flow abnormality”). In some embodiments, flow abnormalities are associated with an increased risk of an unwanted event following neuromodulation therapy. Local flow abnormalities can include, but are not limited to, a region of secondary flow (e.g., turbulent flow, flow separation, and eddy formation), flow impingement, low WSS, high WSS, and/or WSS gradients. Avoidance regions can include one or more pathologic features of vascular disease (e.g., a calcification, a fibromuscular dysplasia, an aneurysm) and/or one or more physiologic features of the vessel (e.g., an ostium, a carina, a taper region, a bifurcation) and/or a combination thereof. In other embodiments (not shown), the method 100 can include identifying, via the processor, target regions of the vessel suitable for neuromodulation therapy The target regions, for example, can be one or more regions of the vessel lacking a local flow abnormality, a physiologic feature, and/or a pathologic feature associated with an increased risk of an unwanted event following neuromodulation therapy.
The target regions can be identified by determining if measured values of the hemodynamic parameters at a given location are within “normal” ranges or above/below values of the hemodynamic parameters indicative of no local flow abnormalities and/or no regions of secondary flow (e.g., threshold hemodynamic parameters). For example, if the hemodynamic parameter is blood pressure, then a blood pressure value within the “normal” range for blood pressure at the given location could trigger a recommendation to deliver neuromodulation therapy at the given location (e.g., a target region). Similarly, the avoidance regions can be identified by determining if measured values of the hemodynamic parameters at the given location are outside “normal” ranges or below/above the values of the hemodynamic parameters indicative of local flow abnormalities and/or regions of secondary flow. For example, a blood pressure value outside of the “normal” range for blood pressure at the given location could trigger a recommendation to avoid delivering neuromodulation therapy at the given location (e.g., an avoidance region). Each corresponding threshold hemodynamic parameter can be determined using empirical, conglomerate, or other suitable data useful to establish the threshold hemodynamic parameter. For example, threshold hemodynamic parameters can be determined for blood flow, blood pressure, blood impedance, and/or other hemodynamic parameters measured using the methods described herein.
The method 100 may use an algorithm executed by the processor to compare one or more hemodynamic parameters against one or more threshold hemodynamic parameters. The threshold hemodynamic parameter can be predetermined or can be calculated before performing the comparison. In some embodiments, the processor that analyzes the hemodynamic parameters can include algorithms that remove any apparent irregular hemodynamic parameter(s) to automatically correct for the anomalies. In other embodiments, the comparison between the one or more hemodynamic parameters and one or more threshold hemodynamic parameters can be made by users, systems, devices, and/or a combination thereof. In further embodiments, the algorithm can use two or more hemodynamic parameters and/or other data to provide a combined hemodynamic parameter that is more closely tied to identifying target and/or avoidance regions of the vessel than any one individual hemodynamic parameter alone.
The method 100 optionally continues by displaying a representation of the vessel including visual markers indicating one or more avoidance regions for not delivering neuromodulation therapy on a user interface (block 150). Also see
With reference to the vessel evaluation results displayed on the user interface, the clinician can deliver neuromodulation catheter 210 to the patient's vessel while monitoring the location of the catheter within the vessel. As described in greater detail below with reference to
In further embodiments, after receiving the catheter location data, the processor can provide a recommendation to the user of whether to proceed with neuromodulation therapy based on whether the current location of assembly 230 includes an identified avoidance region and/or target region. The recommendation can include recommending the user avoid delivering neuromodulation therapy to the one or more identified regions of the patient's vessel (e.g., an avoidance region) or recommending the user deliver neuromodulation therapy to the one or more identified regions (e.g., a target region). In some embodiments, the recommendation can be provided while delivering and/or positioning the neuromodulation catheter. In other embodiments, the recommendation can be provided before or after delivering and/or positioning the catheter.
In some embodiments, the recommendation can be provided to the user via the user interface, for example, by displaying the recommendation on a display or emitting a signal. The signal can be a visual signal, an audio signal, a tactile signal, or a combination thereof. For example, the visual signal can be emitted by a device (e.g., a light) that turns on when assembly 230 is positioned proximate to the one or more identified regions. For example, the recommendation can be a light that turns green when assembly 230 is positioned proximate to or within an identified target region and/or a light that turns red when positioned proximate to or within an identified avoidance region. In other embodiments, the device can be a speaker, a vibration mechanism, or other device suitable for conveying the signal to the user. In addition to the display and/or signal, the recommendation can be provided to the user by exhibiting one or more of the hemodynamic parameters and/or an overall hemodynamic parameter on a visual display or other device configured to receive the hemodynamic parameter(s) and provide the recommendation. In further embodiments, the three-dimensional representation, CFD model, and/or other representation can be stored to guide positioning of the neuromodulation catheter at a later time, and/or computations performed after the image and/or representations were obtained and/or generated. In these embodiments, the image and/or representations can be stored, analyzed, and/or computations performed using a component of the device and/or environment. Furthermore, the processor can also provide a report that distributes the hemodynamic parameters to the user on a smart phone, a computer, a tablet computer, and/or other device including a digital display.
A method of the present technology can include applying neuromodulation energy to at least one of the target regions using a neuromodulation catheter 210. In other embodiments, the target region(s) can be marked as locations for future neuromodulation therapy. When one or more of the hemodynamic parameter(s) are elevated above a corresponding threshold hemodynamic parameter(s) at a location, the location can be identified as an avoidance region. If neuromodulation energy were to be delivered at an identified avoidance region, there is a concern that the patient could have sequelae, such as swelling, edema, stenosis, a tear, rupture, dilation, dissection, and/or thrombus, associated with delivering neuromodulation therapy at that location.
In further embodiments, the method and systems described herein can be used to monitor the vessel following neuromodulation therapy to determine if an unwanted event has occurred or might occur. Changes in blood flow and/or blood pressure following neuromodulation therapy can indicate that an unwanted event might occur at one or more of the regions, or at another region of the vessel. If an unwanted event does occur, the user can opt to treat the patient accordingly.
As shown in
The shaft 220 and the neuromodulation assembly 230 can be 2, 3, 4, 5, 7, or 8 French size or another suitable size. The dimensions (e.g., outer diameter and length) of the distal portion 220b of the shaft 220 can be selected to accommodate the vessels or other body lumens in which the distal portion 220b of the neuromodulation catheter 210 is designed to be delivered. For example, the axial length of the distal portion 220b, may be selected to be no longer than a patient's renal artery (e.g., typically less than 8 cm), and have a deployed or expanded diameter that accommodates the inner diameter of a typical renal artery and/or the branches of the renal artery (e.g., about 2-10 mm, e.g., about 4-8 mm, for the renal artery RA, etc.). In addition, the neuromodulation assembly 230 can include a shape memory portion having shape memory material, such as nickel-titanium alloy, that imparts a helical or spiral shape to the neuromodulation assembly 230 when expanded. In other embodiments, the shaped portion of the neuromodulation assembly 230 can have other dimensions depending on the body lumen within which it is configured to be deployed.
As illustrated, the neuromodulation assembly 230 includes a sensor 240, a transmitter 245, and a plurality of energy delivery elements 260a-g (collectively energy delivery elements 260). In this embodiment, the sensor 240 is disposed at the distal end (e.g., terminal tip) of the distal portion 220b and the transmitter 245 is disposed proximal to the energy delivery elements 260. In other embodiments, the sensor 240 and/or the transmitter 245 can be disposed at different locations suitable for the sensor 240 to detect one or more hemodynamic parameters and/or for the transmitter 245 to transmit the location of the neuromodulation assembly 230 to a receiver 287 in accordance with embodiments described herein. For example, the sensor 240 can be proximal to and/or the transmitter 245 can be distal to one or more energy delivery elements 260. The sensor 240 and the transmitter 245 can be connected to one or more supply wires (not shown) that convey energy to the sensor 240 and transmitter 245. Alternatively, the sensor 240 and/or the transmitter 245 can be coupled operatively to the console 295 by dedicated wires and/or wirelessly (e.g., Bluetooth, radio wave, etc.). In embodiments where neither the sensor 240 nor the transmitter 245 is located at the catheter distal end, the neuromodulation assembly 230 can have an atraumatic tip (not shown). In certain embodiments, the neuromodulation assembly 230 can include more than one sensor 240 and/or transmitter 245. The sensor 240, the transmitter 245 and the neuromodulation assembly 230 can be integrated into a single neuromodulation catheter 210 as illustrated, or one or more of the sensors 240 and/or the transmitters 245 can be provided separately from the neuromodulation catheter 210, as will be discussed below.
The sensor 240 can detect a physiological parameter, such as a hemodynamic parameter, and the transmitter 245 can communicate to the receiver 287 a signal related to the location of the neuromodulation assembly 230 in the vessel. The sensor 240 can include one or more sensors, for example, a blood velocity sensor (e.g., a Doppler laser velocity sensor or an ultrasonic flow meter) that can detect blood flow through a vessel (e.g., renal artery RA), a pressure sensor that measures the blood pressure within the vessel, a blood impedance sensor (e.g., single or multi-electrode) that can determine changes in vessel diameter, and/or other suitable sensors for detecting one or more hemodynamic parameters. As will be appreciated by those skilled in the art, blood is more conductive than vessel tissue and, therefore, vessel impedance, i.e. blood impedance is lower when the vessel has a larger diameter (i.e., when more blood is contained in the vessel) and higher when the vessel has a smaller diameter (i.e., when less blood is contained in the vessel). Accordingly, when the sensor 240 is a single or multi-electrode impedance sensor, blood impedance measurements taken by the sensor 240 can be correlated to changes in vessel diameter, segmental volume, and/or cross-sectional area (i.e., a hemodynamic response). In some embodiments, the blood impedance measurements can be used to assess the efficacy of the neuromodulation treatment. Similar to vessel diameter, blood flow and blood pressure are expected to change in response to a stimulus, and these changes are expected to occur to a lesser degree after neuromodulation than before neuromodulation. Therefore, the changes in blood flow and/or vessel pressure measurements caused by an electrical or pharmacological stimulus can be detected before and after neuromodulation and then compared to threshold values to determine the efficacy of neuromodulation therapy. Further embodiments of monitoring hemodynamic responses to stimuli are disclosed in PCT Patent Application Number PCT/US15/534999, filed Oct. 1, 2015, entitled “Systems and Methods for Evaluating Neuromodulation Therapy via Hemodynamic Responses”, which is incorporated by reference herein in its entirety.
In some embodiments, the sensor 240 can detect more than one hemodynamic parameter in the vessel. For example, the sensor 240 can include a sensor configured to detect blood flow and blood pressure in the renal artery. In other embodiments, the sensor 240 can include different or additional sensors that detect and/or record other information such as one or more of temperature (e.g., thermocouple, thermistor, etc.), optical, chemical, and/or other parameters. The sensor 240 sensor(s) can further be configured to record data associated with the detected hemodynamic parameters. In some embodiments, the recordings can be made by another component of the system 200.
The transmitter 245 can include one or more sensors, for example, a first sensor, a second sensor, a third sensor, a fourth sensor, etc. configured to monitor the location of the neuromodulation assembly 230 in the vessel. In some embodiments, each sensor of the transmitter 245 can be configured to monitor the location of specific energy delivery elements 260 (e.g., electrodes). For example, the first sensor can be configured to monitor a location of energy delivery elements 260a and 260b, the second sensor can be configured to monitor the location of energy delivery elements 260c and 260d, the third sensor can be configured to monitor the location of energy delivery elements 260e and 260f, and the fourth sensor can be configured to monitor the location of energy delivery element 260g. In other embodiments, each sensor can have a certain range and can monitor the location of any portion of the neuromodulation assembly 230, or the location of the transmitter relative to any features of the vessel (e.g., wall, ostium, bifurcation, etc.) located within the range. The sensor(s) of the transmitter 245 can further be configured to record data associated with the monitored location. In some embodiments, the location recordings can be made by another component of the system 200.
In other embodiments, the neuromodulation assembly 230 can have fewer or more than seven energy delivery elements 260. As illustrated in
The energy delivery elements 260 (e.g., electrodes) can be positioned on the neuromodulation assembly 230 in one or multiple planes in a variety of patterns. In the illustrated embodiment, the energy delivery elements 260 are positioned on the shape memory portion of the neuromodulation assembly 230 such that many or all of the energy delivery elements 260 press against or otherwise contact the interior vessel wall (e.g., renal artery RA wall). In other embodiments, multiple energy delivery elements 260 can be positioned in the same plane orthogonal to the renal artery RA to deliver stimuli and/or obtain multiple recordings in the same plane of the interior vessel wall. When in contact with the interior vessel wall, the energy delivery elements 260 and/or another type of energy delivery element can deliver neuromodulation energy to the target region to modulate or ablate nerves proximate to the target region. It is expected that a successful or effective neuromodulation treatment or therapy (i.e., when nerves are ablated to a desired degree) stops or attenuates nerve activity.
Although the illustrated embodiment of the neuromodulation assembly 230 is configured with the spiral/helix-shape, in other embodiments, the distal portion 220b of the shaft 220 can have other suitable shapes (e.g., semi-circular, curved, straight, etc.), and/or the neuromodulation catheter 210 can include multiple support members configured to carry one or more energy delivery elements 260 and press the energy delivery elements 260 against the interior vessel wall. Other suitable devices and technologies are described in, for example, U.S. patent application Ser. No. 12/910,631, filed Oct. 22, 2010; U.S. patent application Ser. No. 13/279,205, filed Oct. 21, 2011; U.S. patent application Ser. No. 13/279,330, filed Oct. 23, 2011; U.S. patent application Ser. No. 13/281,360, filed Oct. 25, 2011; U.S. patent application Ser. No. 13/281,361, filed Oct. 25, 2011; PCT Application No. PCT/US11/57754, filed Oct. 25, 2011; U.S. Provisional Patent Application No. 71/646,218, filed May 5, 2012; U.S. patent application Ser. No. 13/793,647, filed Mar. 11, 2013; U.S. Provisional Patent Application No. 71/961,874, filed Oct. 24, 2013; and U.S. patent application Ser. No. 13/670,452, filed Nov. 7, 2012. All of the foregoing applications are incorporated herein by reference in their entireties. Non-limiting examples of devices and systems include the Symplicity™ RF ablation catheter and the Symplicity Spyral™ multielectrode RF ablation catheter.
The console 295 of system 200 can be configured to control, monitor, supply, and/or otherwise support operation of the neuromodulation catheter 210 and the CFD modeling of
In selected embodiments, the console 295 and neuromodulation catheter 210 may be configured to deliver a monopolar electric field via one or more of the energy delivery elements 260. In such embodiments, a neutral or dispersive energy delivery element (not shown) may be electrically connected to the console 295 and attached to the exterior of the patient. In embodiments including multiple energy delivery elements 260, the energy delivery elements 260 may deliver power independently in a monopolar fashion, either simultaneously, selectively, or sequentially, and/or may deliver power between any desired combinations of the energy delivery elements 260 in a bipolar fashion. In addition, a user may manually select which energy delivery elements 260 are activated for power delivery in order to form highly customized lesion(s) within the lumen (e.g., renal artery), as desired.
The controller 280 and processor 285 can define a computing device that includes memory and is configured to receive and store imaging data, hemodynamic data (e.g., measured values of a hemodynamic parameter detected by the sensor 240) and/or the location data (e.g., magnetic signals transmitted by the transmitter 245). The memory can be configured to store instructions that, when executed by the computing device, cause the system 200 to perform certain operations in accordance with the present technology, such as executing embodiments of blocks 110, 120, 130, 140 and 150 of method 100 described above with respect to
In addition to avoiding delivering neuromodulation energy at one or more avoidance regions as described above, additional embodiments of methods and systems of the present technology can determine efficacy and/or risk to optimize a neuromodulation procedure. For example, the sensor 240 can be positioned proximal to the treatment region to detect or measure one or more hemodynamic parameter(s) after applying neuromodulatory energy. In addition, the transmitter 245 can be positioned near (e.g., proximal or distal) to the treatment region to convey information to the user about the location of the neuromodulation assembly 230 in the vessel. The controller 280 can include algorithms that generate a comparison of the patient's pre-neuromodulation and post-neuromodulation information (e.g., hemodynamic parameters, imaging data, etc.). Since one or more hemodynamic parameters can change in response to energy delivery, the comparison can provide the user with an indication of whether neuromodulation therapy was effective, and/or whether there is risk of, or an actual unwanted event. In certain embodiments, the comparison can be referenced against a standardized or patient-specific threshold change or level indicative of therapeutically effective neuromodulation and/or a risk of an unwanted event. The comparison can be provided to the user via the user interface 297 or other component (e.g., a monitor). Based on the comparison, the user can determine whether the neuromodulation therapy achieved the desired effect, or if the therapy affected hemodynamic parameter(s) and/or a structural feature of the vessel (e.g., wall thickness, rupture, intimal delamination, etc.). If the comparison indicates that neuromodulation therapy was not effective and/or that the risk of experiencing an unwanted event has increased, subsequent monitoring and/or subsequent courses of treatment can be performed. For example, the neuromodulation assembly 230 can be repositioned along the vessel (e.g., renal artery RA) and/or rotated to modulate nerves at a different position or in a different plane.
During a procedure, the neuromodulation assembly 230 extends distally of the distal portion 330 of the guide catheter 320 and into the vessel lumen. As the neuromodulation assembly 230 is advanced through the vessel lumen, for example, the sensor 240 senses laminar blood flow through a proximal portion of the lumen. When the neuromodulation assembly encounters potential avoidance regions such as a stenosis 351, and/or a bifurcation 315, the sensor 240 detects a change in the previously laminar blood flow. The sensor 240 transmits the blood flow data to the receiver 287 and, as described above, other components of the system 200 generate the CFD model based, in part, on the blood flow data. As described above, the system 200 identifies and recommends avoidance regions and target regions for delivering neuromodulation energy.
Once positioned in the target blood vessel, the neuromodulation assembly 230 is transformed from a low-profile delivery state (not shown) for delivery (e.g., intravascularly through the aorta) to a deployed state (e.g., radially expanded state). When deployed, the energy delivery elements 260 are pressed against the inner wall of the vessel and neuromodulation energy can be selectively delivered to the identified target regions. After delivering neuromodulation energy, the system 200 is configured to sense post-neuromodulation therapy parameters and determine the efficacy and/or the risk of an unwanted event as described above. If necessary, the user can reposition the neuromodulation assembly 230 to deliver additional neuromodulation therapy at one or more different identified target locations. To reposition the neuromodulation assembly 230, the user can return the assembly 230 to the low-profile delivery state and re-deploy the neuromodulation assembly 230 at a new location. In some embodiments, the location of the neuromodulation assembly 230 during positioning, deployment, repositioning, re-deployment, and/or a combination thereof can be displayed on the user interface 297 in real-time.
In some embodiments, the neuromodulation assembly 230 (not shown) can be positioned in the vessel 405 while the user is viewing the representation 400. Referring in part to
In some embodiments, an audible signal, a tactile signal, or a combination thereof can be combined with the representation 400 to alert the user of a location of the neuromodulation assembly 230. For example, the audible signal and/or the tactile signal can alert the user when one or more energy delivery elements 260 of the neuromodulation assembly 230 are located at an identified avoidance region 460 or alternatively at an identified target region 440. Alternatively, the audible signal and/or the tactile signal can include multiple signals wherein each signal (e.g., a tone, a vibration, repetition of the signal, etc.) corresponds to a particular energy delivery element 260 positioned at a particular region. Using a multi-electrode catheter such as catheter 210, the clinician may operate console 295 to test each energy delivery element 260 individually for a signal indicating the potential risk or benefit of administering neuromodulation energy at each element's current location. For example, a first signal can correspond to an energy delivery element 260 located within an avoidance region 460, a second signal can correspond to a second energy delivery element 260 located within a potential region 450, and a third signal can correspond to a third energy delivery element 260 located within a target region 440. Similar to the displayed indicators, the audible signals and/or the tactile signals can be transmitted to the user in real-time as the neuromodulation assembly 230 is being positioned regardless of whether the location of the neuromodulation assembly 230 is visible on representation 400 in real-time. In certain embodiments, only visual indicators are displayed on the representation 400, only audible signals are transmitted to the user, or only tactile signals are transmitted to the user.
In other embodiments, the transmitter 245 can be at the distal portion 220b of the shaft 220 instead of the sensor, and the sensor 240 can be carried by the guidewire 555. In embodiments where the neuromodulation catheter 210 includes more than one sensor 240 and/or more than one transmitter 245, some of the sensors and/or some of the transmitters can be carried by the distal portion 220b of the shaft 220 and others can be carried by the guidewire 555. In other embodiments, the sensor 240 can be mounted on a portion of a guide catheter that is insertable into the vessel receiving neuromodulation treatment.
In the illustrated embodiment, the sensor 240 is coupled to shaft 220 and delivered through the guide catheter 320 with the neuromodulation assembly 230 to a first position along the vessel (e.g., renal artery RA). Once catheter 210 is positioned, the guidewire 555 with the transmitter 245 is delivered through the guide catheter 320 to a second position proximate the first position. For purposes of clarity,
As illustrated in
As illustrated in
In addition to the above physiologic changes in vascular geometry, blood flow can also be altered by pathological events, such as changes in the vessel wall. For example, portions of the vessel wall that have thickened such as at a stenosis 351 impinge the laminar flow 754 in region 750. As illustrated, the left lumen 718 narrows at stenosis 351, resulting in laminar flow 754 becoming turbulent flow 756 along the distal portion of the region of impinged flow 750. Vascular calcification 720 occurs by formation and/or deposit of calcium 727 in the vessel wall. While calcium deposits can be located in the intima 721 and/or adventitia 723, deposits are most commonly found in the media 725. A portion of the vessel wall having a calcification 720 (e.g., calcium deposits) is less elastic, having an impaired ability to respond to changes in blood flow, blood pressure, etc. compared to a non-calcified region.
As illustrated in
The vessel wall can also be altered by the formation of an aneurysm, which is a localized dilation or ballooning of the vessel wall that may be associated with hypertension and/or may occur at weak portions of the vessel wall. Aneurysms are often classified by their location, for example, arterial, venous, cardiac, coronary, aorta, brain, legs, kidneys, and capillaries. As illustrated in
In addition to the method 100, systems 200, 500, and embodiments thereof described herein regarding assessing hemodynamics for optimizing delivery of neuromodulation therapy, image guidance, e.g., computed tomography (CT), fluoroscopy, intravascular ultrasound (IVUS), optical coherence tomography (OCT), intracardiac echocardiography (ICE), or another suitable guidance modality, or combinations thereof, may also aid the clinician's positioning and manipulation of the neuromodulation catheter 210 in accordance with the present technology. For example, a fluoroscopy system (e.g., including a flat-panel detector, x-ray, or c-arm) can be rotated to accurately visualize and identify the target treatment region. In other embodiments, the treatment region can be determined using IVUS, OCT, and/or other suitable image mapping modalities that can correlate the target treatment region with an identifiable anatomical structure (e.g., a spinal feature) and/or a radiopaque ruler (e.g., positioned under or on the patient) before delivering the neuromodulation assembly 230. Further, in some embodiments, image guidance components (e.g., IVUS, OCT) may be integrated with the neuromodulation catheter 210 and/or run in parallel with the neuromodulation catheter 210 to provide image guidance during positioning of the neuromodulation assembly 230. For example, image guidance components (e.g., IVUS or OCT) can be coupled to the neuromodulation assembly 230 to provide three-dimensional images of the vasculature proximate the target region to facilitate positioning or deploying the neuromodulation assembly 230 within the target vessel. As described above, the method 100, systems 200, 500, and embodiments thereof can include determining the location of avoidance regions and/or target regions for delivering neuromodulation therapy and transmitting location information to the user. The image guidance modalities described herein can be used in conjunction with methods, systems, and embodiments of the present technology to provide location information of the neuromodulation catheter 210 to the user in real-time.
Energy from the electrodes 260 (
Hypothermic effects may also provide neuromodulation. For example, a cryotherapeutic applicator may be used to cool tissue at a target region to provide therapeutically-effective direct cell injury (e.g., necrosis), vascular injury (e.g., starving the cell from nutrients by damaging supplying blood vessels), and sublethal hypothermia with subsequent apoptosis. Exposure to cryotherapeutic cooling can cause acute cell death (e.g., immediately after exposure) and/or delayed cell death (e.g., during tissue thawing and subsequent hyperperfusion). Embodiments of the present technology can include cooling a structure at or near an inner surface of a renal artery wall such that proximate (e.g., adjacent) tissue is effectively cooled to a depth where sympathetic renal nerves reside. For example, the cooling structure is cooled to the extent that it causes therapeutically effective, cryogenic renal-nerve modulation. Sufficiently cooling at least a portion of a sympathetic renal nerve is expected to slow or potentially block conduction of neural signals to produce a prolonged or permanent reduction in renal sympathetic activity.
As illustrated in
The device 1100 can include, for example, one or more input devices 1120 providing input to a central processing unit (“CPU”; processor) 1110, notifying the CPU 1110 of actions. The actions are typically mediated by a hardware controller that interprets the signals received from the input device and communicates the information to the CPU 1110 using a communication protocol. The input devices 1120 include, for example, a receiver for receiving signals from a monitoring device (e.g., the sensor 240 and/or the transmitter 245 described with reference to
The CPU 1110 can be a single processing unit or multiple processing units in a device or distributed across multiple devices. CPU 1110 can be coupled to other hardware devices, for example, with the use of a bus, such as a PCI bus or SCSI bus. The CPU 1110 can communicate with a hardware controller for devices, such as a display 1130. The display 1130, which can be the display 297 of the console 295 (
In some implementations, the device 1100 also includes a communication device capable of communicating wirelessly or wire-based with a network node. The communication device can communicate with another device or a server through a network using, for example, TCP/IP protocols. Device 1100 can utilize the communication device to distribute operations across multiple network devices.
The device 1100 can execute embodiments of blocks 110, 120, 130, 140 and 150 of method 100 described above with respect to
Some implementations can be operational with numerous other general purpose or special purpose computing system environments or configurations. Examples of well-known computing systems, environments, and/or configurations that may be suitable for use with the technology include, but are not limited to, personal computers, server computers, handheld or laptop devices, cellular telephones, wearable electronics, tablet devices, multiprocessor systems, microprocessor-based systems, set-top boxes, programmable consumer electronics, network PCs, minicomputers, mainframe computers, distributed computing environments that include any of the above systems or devices, or the like.
In some implementations, server 1210 can be an edge server that receives client requests and coordinates fulfillment of those requests through other servers, such as servers 1220A-C. The server computing devices (not shown) can comprise computing systems, such as device 1100 (
The client computing devices 1205 and the server computing devices 1210 and 1220 can each act as a server or client to other server/client devices. The server 1210 can connect to a database 1215. The servers 1220A-C can each connect to corresponding databases 1225A-C. As discussed above, each server 1220 can correspond to a group of servers, and each of these servers can share a database or can have their own database. The databases 1215 and 1225 can warehouse (e.g., store) information such as raw data (e.g., related to patient hemodynamic parameters, three-dimensional representations, CFD representations, representations), algorithms (e.g., deriving hemodynamic parameters, digital three-dimensional representations, CFD representations, representations), other patient information, and/or other information necessary for the implementation of the systems and methods described above with respect to
The network 1230 can be a local area network (LAN) or a wide area network (WAN), but can also be other wired or wireless networks. The network 1230 may be the Internet or some other public or private network. The client computing devices 1205 can be connected to the network 1230 through a network interface, such as by wired or wireless communication. While the connections between the server 1210 and servers 1220 are shown as separate connections, these connections can be any kind of local, wide area, wired, or wireless network, including the network 1230 or a separate public or private network.
Renal neuromodulation is the partial or complete incapacitation or other effective disruption of nerves of the kidneys (e.g., nerves terminating in the kidneys or in structures closely associated with the kidneys). In particular, renal neuromodulation can include inhibiting, reducing, and/or blocking neural communication along neural fibers (e.g., efferent and/or afferent neural fibers) of the kidneys. Such incapacitation can be long-term (e.g., permanent or for periods of months, years, or decades) or short-term (e.g., for periods of minutes, hours, days, or weeks). Renal neuromodulation is expected to contribute to the systemic reduction of sympathetic tone or drive and/or to benefit at least some specific organs and/or other bodily structures innervated by sympathetic nerves. Accordingly, renal neuromodulation is expected to be useful in treating clinical conditions associated with systemic sympathetic overactivity or hyperactivity, particularly conditions associated with central sympathetic overstimulation. For example, renal neuromodulation is expected to efficaciously treat hypertension, heart failure, acute myocardial infarction, metabolic syndrome, insulin resistance, diabetes, left ventricular hypertrophy, chronic and end stage renal disease, inappropriate fluid retention in heart failure, cardio-renal syndrome, polycystic kidney disease, polycystic ovary syndrome, osteoporosis, erectile dysfunction, and sudden death, among other conditions.
Renal neuromodulation can be electrically-induced, thermally-induced, chemically-induced, or induced in another suitable manner or combination of manners at one or more suitable target regions during a treatment procedure. The target region can be within or otherwise proximate to a renal lumen (e.g., a renal artery, a ureter, a renal pelvis, a major renal calyx, a minor renal calyx, or another suitable structure), and the treated tissue can include perivascular tissue (at least proximate to a wall of the renal lumen). For example, with regard to a renal artery, a treatment procedure can include modulating nerves in the renal plexus, which lay intimately within or adjacent to the adventitia of the renal artery.
Renal neuromodulation can include a cryotherapeutic treatment modality alone or in combination with another treatment modality. Cryotherapeutic treatment can include cooling tissue at a target region in a manner that modulates neural function. For example, sufficiently cooling at least a portion of a sympathetic renal nerve can slow or potentially block conduction of neural signals to produce a prolonged or permanent reduction in renal sympathetic activity. This effect can occur as a result of cryotherapeutic tissue damage, which can include, for example, direct cell injury (e.g., necrosis), vascular or luminal injury (e.g., starving cells from nutrients by damaging supplying blood vessels), and/or sublethal hypothermia with subsequent apoptosis. Exposure to cryotherapeutic cooling can cause acute cell death (e.g., immediately after exposure) and/or delayed cell death (e.g., during tissue thawing and subsequent hyperperfusion). Neuromodulation using a cryotherapeutic treatment in accordance with embodiments of the present technology can include cooling a structure proximate an inner surface of a body lumen wall such that tissue is effectively cooled to a depth where sympathetic renal nerves reside. For example, in some embodiments, a cooling assembly of a cryotherapeutic device can be cooled to the extent that it causes therapeutically-effective, cryogenic renal neuromodulation. In other embodiments, a cryotherapeutic treatment modality can include cooling that is not configured to cause neuromodulation. For example, the cooling can be at or above cryogenic temperatures and can be used to control neuromodulation via another treatment modality (e.g., to protect tissue from neuromodulating energy).
Renal neuromodulation can include an electrode-based or transducer-based treatment modality alone or in combination with another treatment modality. Electrode-based or transducer-based treatment can include delivering electricity and/or another form of energy to tissue at a treatment location to stimulate and/or heat the tissue in a manner that modulates neural function. For example, sufficiently stimulating and/or heating at least a portion of a sympathetic renal nerve can slow or potentially block conduction of neural signals to produce a prolonged or permanent reduction in renal sympathetic activity. A variety of suitable types of energy can be used to stimulate and/or heat tissue at a treatment location. For example, neuromodulation in accordance with embodiments of the present technology can include delivering RF energy, pulsed electrical energy, microwave energy, optical energy, focused ultrasound energy (e.g., high-intensity focused ultrasound energy), or another suitable type of energy alone or in combination. An electrode or transducer used to deliver this energy can be used alone or with other electrodes or transducers in a multi-electrode or multi-transducer array. Furthermore, the energy can be applied from within the body (e.g., within the vasculature or other body lumens in a catheter-based approach) and/or from outside the body (e.g., via an applicator positioned outside the body). Furthermore, energy can be used to reduce damage to non-targeted tissue when targeted tissue adjacent to the non-targeted tissue is subjected to neuromodulating cooling.
Neuromodulation using focused ultrasound energy (e.g., high-intensity focused ultrasound energy) can be beneficial relative to neuromodulation using other treatment modalities. Focused ultrasound is an example of a transducer-based treatment modality that can be delivered from outside the body. Focused ultrasound treatment can be performed in close association with imaging (e.g., magnetic resonance, computed tomography, fluoroscopy, ultrasound (e.g., intravascular or intraluminal), optical coherence tomography, or another suitable imaging modality). For example, imaging can be used to identify an anatomical position of a treatment location (e.g., as a set of coordinates relative to a reference point). The coordinates can then be entered into a focused ultrasound device configured to change the power, angle, phase, or other suitable parameters to generate an ultrasound focal zone at the location corresponding to the coordinates. The focal zone can be small enough to localize therapeutically-effective heating at the treatment location while partially or fully avoiding potentially harmful disruption of nearby structures. To generate the focal zone, the ultrasound device can be configured to pass ultrasound energy through a lens, and/or the ultrasound energy can be generated by a curved transducer or by multiple transducers in a phased array (curved or straight).
Heating effects of electrode-based or transducer-based treatment can include ablation and/or non-ablative alteration or damage (e.g., via sustained heating and/or resistive heating). For example, a treatment procedure can include raising the temperature of target neural fibers to a target temperature above a first threshold to achieve non-ablative alteration, or above a second, higher threshold to achieve ablation. The target temperature can be higher than about body temperature (e.g., about 37° C.) but less than about 45° C. for non-ablative alteration, and the target temperature can be higher than about 45° C. for ablation. Heating tissue to a temperature between about body temperature and about 45° C. can induce non-ablative alteration, for example, via moderate heating of target neural fibers or of vascular or luminal structures that perfuse the target neural fibers. In cases where vascular structures are affected, the target neural fibers can be denied perfusion resulting in necrosis of the neural tissue. Heating tissue to a target temperature higher than about 45° C. (e.g., higher than about 70° C.) can induce ablation, for example, via substantial heating of target neural fibers or of vascular or luminal structures that perfuse the target fibers. In some patients, it can be desirable to heat tissue to temperatures that are sufficient to ablate the target neural fibers or the vascular or luminal structures, but that are less than about 40° C. (e.g., less than about 95° C., less than about 90° C., or less than about 85° C.).
Renal neuromodulation can include a chemical-based treatment modality alone or in combination with another treatment modality. Neuromodulation using chemical-based treatment can include delivering one or more chemicals (e.g., drugs or other agents) to tissue at a treatment location in a manner that modulates neural function. The chemical, for example, can be selected to affect the treatment location generally or to selectively affect some structures at the treatment location over other structures. The chemical, for example, can be guanethidine, ethanol, phenol, a neurotoxin, or another suitable agent selected to alter, damage, or disrupt nerves. A variety of suitable techniques can be used to deliver chemicals to tissue at a treatment location. For example, chemicals can be delivered via one or more needles originating outside the body or within the vasculature or other body lumens. In an intravascular example, a catheter can be used to intravascularly position a therapeutic element including a plurality of needles (e.g., micro-needles) that can be retracted or otherwise blocked before deployment. In other embodiments, a chemical can be introduced into tissue at a treatment location via simple diffusion through a body lumen wall, electrophoresis, or another suitable mechanism. Similar techniques can be used to introduce chemicals that are not configured to cause neuromodulation, but rather to facilitate neuromodulation via another treatment modality.
As noted previously, the sympathetic nervous system (SNS) is a branch of the autonomic nervous system along with the enteric nervous system and parasympathetic nervous system. It is always active at a basal level (called sympathetic tone) and becomes more active during times of stress. Like other parts of the nervous system, the sympathetic nervous system operates through a series of interconnected neurons. Sympathetic neurons are frequently considered part of the peripheral nervous system (PNS), although many lie within the central nervous system (CNS). Sympathetic neurons of the spinal cord (which is part of the CNS) communicate with peripheral sympathetic neurons via a series of sympathetic ganglia. Within the ganglia, spinal cord sympathetic neurons join peripheral sympathetic neurons through synapses. Spinal cord sympathetic neurons are therefore called presynaptic (or preganglionic) neurons, while peripheral sympathetic neurons are called postsynaptic (or postganglionic) neurons.
At synapses within the sympathetic ganglia, preganglionic sympathetic neurons release acetylcholine, a chemical messenger that binds and activates nicotinic acetylcholine receptors on postganglionic neurons. In response to this stimulus, postganglionic neurons principally release noradrenaline (norepinephrine). Prolonged activation may elicit the release of adrenaline from the adrenal medulla.
Once released, norepinephrine and epinephrine bind adrenergic receptors on peripheral tissues. Binding to adrenergic receptors causes a neuronal and hormonal response. The physiologic manifestations include pupil dilation, increased heart rate, occasional vomiting, and increased blood pressure. Increased sweating is also seen due to binding of cholinergic receptors of the sweat glands.
The sympathetic nervous system is responsible for up- and down-regulating many homeostatic mechanisms in living organisms. Fibers from the SNS innervate tissues in almost every organ system, providing at least some regulatory function to physiological features as diverse as pupil diameter, gut motility, and urinary output. This response is also known as sympatho-adrenal response of the body, as the preganglionic sympathetic fibers that end in the adrenal medulla (but also all other sympathetic fibers) secrete acetylcholine, which activates the secretion of adrenaline (epinephrine) and to a lesser extent noradrenaline (norepinephrine). Therefore, this response that acts primarily on the cardiovascular system is mediated directly via impulses transmitted through the sympathetic nervous system and indirectly via catecholamines secreted from the adrenal medulla.
Science typically looks at the SNS as an automatic regulation system, that is, one that operates without the intervention of conscious thought. Some evolutionary theorists suggest that the sympathetic nervous system operated in early organisms to maintain survival as the sympathetic nervous system is responsible for priming the body for action. One example of this priming is in the moments before waking, in which sympathetic outflow spontaneously increases in preparation for action.
1. The Sympathetic Chain
As shown in
In order to reach the target organs and glands, the axons should travel long distances in the body, and to accomplish this, many axons relay their message to a second cell through synaptic transmission. The ends of the axons link across a space, the synapse, to the dendrites of the second cell. The first cell (the presynaptic cell) sends a neurotransmitter across the synaptic cleft where it activates the second cell (the postsynaptic cell). The message is then carried to the final destination.
In the SNS and other components of the peripheral nervous system, these synapses are made at regions called ganglia, discussed above. The cell that sends its fiber is called a preganglionic cell, while the cell whose fiber leaves the ganglion is called a postganglionic cell. As mentioned previously, the preganglionic cells of the SNS are located between the first thoracic (T1) segment and third lumbar (L3) segments of the spinal cord. Postganglionic cells have their cell bodies in the ganglia and send their axons to target organs or glands.
The ganglia include not just the sympathetic trunks but also the cervical ganglia (superior, middle and inferior), which sends sympathetic nerve fibers to the head and thorax organs, and the celiac and mesenteric ganglia (which send sympathetic fibers to the gut).
2. Innervation of the Kidneys
As
Preganglionic neuronal cell bodies are located in the intermediolateral cell column of the spinal cord. Preganglionic axons pass through the paravertebral ganglia (they do not synapse) to become the lesser splanchnic nerve, the least splanchnic nerve, first lumbar splanchnic nerve, second lumbar splanchnic nerve, and travel to the celiac ganglion, the superior mesenteric ganglion, and the aorticorenal ganglion. Postganglionic neuronal cell bodies exit the celiac ganglion, the superior mesenteric ganglion, and the aorticorenal ganglion to the renal plexus (RP) and are distributed to the renal vasculature.
3. Renal Sympathetic Neural Activity
Messages travel through the SNS in a bidirectional flow. Efferent messages may trigger changes in different parts of the body simultaneously. For example, the sympathetic nervous system may accelerate heart rate; widen bronchial passages; decrease motility (movement) of the large intestine; constrict blood vessels; increase peristalsis in the esophagus; cause pupil dilation, piloerection (goose bumps) and perspiration (sweating); and raise blood pressure. Afferent messages carry signals from various organs and sensory receptors in the body to other organs and, particularly, the brain.
Hypertension, heart failure, and chronic kidney disease are a few of many disease states that result from chronic activation of the SNS, especially the renal sympathetic nervous system. Chronic activation of the SNS is a maladaptive response that drives the progression of these disease states. Pharmaceutical management of the renin-angiotensin-aldosterone system (RAAS) has been a longstanding, but somewhat ineffective, approach for reducing over-activity of the SNS.
As mentioned above, the renal sympathetic nervous system has been identified as a major contributor to the complex pathophysiology of hypertension, states of volume overload (such as heart failure), and progressive renal disease, both experimentally and in humans. Studies employing radiotracer dilution methodology to measure overflow of norepinephrine from the kidneys to plasma revealed increased renal norepinephrine (NE) spillover rates in patients with essential hypertension, particularly so in young hypertensive subjects, which in concert with increased NE spillover from the heart, is consistent with the hemodynamic profile typically seen in early hypertension and characterized by an increased heart rate, cardiac output, and renovascular resistance. It is now known that essential hypertension is commonly neurogenic, often accompanied by pronounced sympathetic nervous system overactivity.
Activation of cardiorenal sympathetic nerve activity is even more pronounced in heart failure, as demonstrated by an exaggerated increase of NE overflow from the heart and the kidneys to plasma in this patient group. In line with this notion is the recent demonstration of a strong negative predictive value of renal sympathetic activation on all-cause mortality and heart transplantation in patients with congestive heart failure, which is independent of overall sympathetic activity, glomerular filtration rate, and left ventricular ejection fraction. These findings support the notion that treatment regimens that are designed to reduce renal sympathetic stimulation have the potential to improve survival in patients with heart failure.
Both chronic and end stage renal disease are characterized by heightened sympathetic nervous activation. In patients with end stage renal disease, plasma levels of norepinephrine above the median have been demonstrated to be predictive for both all-cause death and death from cardiovascular disease. This is also true for patients suffering from diabetic or contrast nephropathy. There is compelling evidence suggesting that sensory afferent signals originating from the diseased kidneys are major contributors to initiating and sustaining elevated central sympathetic outflow in this patient group; this facilitates the occurrence of the well-known adverse consequences of chronic sympathetic overactivity, such as hypertension, left ventricular hypertrophy, ventricular arrhythmias, sudden cardiac death, insulin resistance, diabetes, and metabolic syndrome.
(i) Renal Sympathetic Efferent Activity
Sympathetic nerves to the kidneys terminate in the blood vessels, the juxtaglomerular apparatus and the renal tubules. Stimulation of the renal sympathetic nerves causes increased renin release, increased sodium (Na+) reabsorption, and a reduction of renal blood flow. These components of the neural regulation of renal function are considerably stimulated in disease states characterized by heightened sympathetic tone and clearly contribute to the rise in blood pressure in hypertensive patients. The reduction of renal blood flow and glomerular filtration rate as a result of renal sympathetic efferent stimulation is likely a cornerstone of the loss of renal function in cardio-renal syndrome, which is renal dysfunction as a progressive complication of chronic heart failure, with a clinical course that typically fluctuates with the patient's clinical status and treatment. Pharmacologic strategies to thwart the consequences of renal efferent sympathetic stimulation include centrally acting sympatholytic drugs, beta blockers (intended to reduce renin release), angiotensin converting enzyme inhibitors and receptor blockers (intended to block the action of angiotensin II and aldosterone activation consequent to renin release) and diuretics (intended to counter the renal sympathetic mediated sodium and water retention). However, the current pharmacologic strategies have significant limitations including limited efficacy, compliance issues, side effects and others.
(ii) Renal Sensory Afferent Nerve Activity
The kidneys communicate with integral structures in the central nervous system via renal sensory afferent nerves. Several forms of “renal injury” may induce activation of sensory afferent signals. For example, renal ischemia, reduction in stroke volume or renal blood flow, or an abundance of adenosine enzyme may trigger activation of afferent neural communication. As shown in
The physiology therefore suggests that (i) modulation of tissue with efferent sympathetic nerves will reduce inappropriate renin release, salt retention, and reduction of renal blood flow, and that (ii) modulation of tissue with afferent sensory nerves will reduce the systemic contribution to hypertension and other disease states associated with increased central sympathetic tone through its direct effect on the posterior hypothalamus as well as the contralateral kidney. In addition to the central hypotensive effects of afferent renal denervation, a desirable reduction of central sympathetic outflow to various other sympathetically innervated organs such as the heart and the vasculature is anticipated.
B. Additional Clinical Benefits of Renal Denervation
As provided above, renal denervation is likely to be valuable in the treatment of several clinical conditions characterized by increased overall and particularly renal sympathetic activity such as hypertension, metabolic syndrome, insulin resistance, diabetes, left ventricular hypertrophy, chronic end stage renal disease, inappropriate fluid retention in heart failure, cardio-renal syndrome, and sudden death. Since the reduction of afferent neural signals contributes to the systemic reduction of sympathetic tone/drive, renal denervation might also be useful in treating other conditions associated with systemic sympathetic hyperactivity. Accordingly, renal denervation may also benefit other organs and bodily structures innervated by sympathetic nerves, including those identified in
C. Achieving Intravascular Access to the Renal Artery
In accordance with the present technology, neuromodulation of a left and/or right renal plexus (RP), which is intimately associated with a left and/or right renal artery, may be achieved through intravascular access. As
As
As will be described in greater detail later, the femoral artery may be accessed and cannulated at the base of the femoral triangle just inferior to the midpoint of the inguinal ligament. A catheter may be inserted percutaneously into the femoral artery through this access region, passed through the iliac artery and aorta, and placed into either the left or right renal artery. This comprises an intravascular path that offers minimally invasive access to a respective renal artery and/or other renal blood vessels.
The wrist, upper arm, and shoulder region provide other locations for introduction of catheters into the arterial system. For example, catheterization of either the radial, brachial, or axillary artery may be utilized in select cases. Catheters introduced via these access points may be passed through the subclavian artery on the left side (or via the subclavian and brachiocephalic arteries on the right side), through the aortic arch, down the descending aorta and into the renal arteries using standard angiographic technique.
D. Properties and Characteristics of the Renal Vasculature
Since neuromodulation of a left and/or right renal plexus (RP) may be achieved in accordance with the present technology through intravascular access, properties and characteristics of the renal vasculature may impose constraints upon and/or inform the design of apparatus, systems, and methods for achieving such renal neuromodulation. Some of these properties and characteristics may vary across the patient population and/or within a specific patient across time, as well as in response to disease states, such as hypertension, chronic kidney disease, vascular disease, end-stage renal disease, insulin resistance, diabetes, metabolic syndrome, etc. These properties and characteristics, as explained herein, may have bearing on the efficacy of the procedure and the specific design of the intravascular device. Properties of interest may include, for example, material/mechanical, spatial, fluid dynamic/hemodynamic, and/or thermodynamic properties.
As discussed previously, a catheter may be advanced percutaneously into either the left or right renal artery via a minimally invasive intravascular path. However, minimally invasive renal arterial access may be challenging, for example, because as compared to some other arteries that are routinely accessed using catheters, the renal arteries are often extremely tortuous, may be of relatively small diameter, and/or may be of relatively short length. Furthermore, renal arterial atherosclerosis is common in many patients, particularly those with cardiovascular disease. Renal arterial anatomy also may vary significantly from patient to patient, which further complicates minimally invasive access. Significant inter-patient variation may be seen, for example, in relative tortuosity, diameter, length, and/or atherosclerotic plaque burden, as well as in the take-off angle at which a renal artery branches from the aorta. Apparatus, systems, and methods for achieving renal neuromodulation via intravascular access, should account for these and other aspects of renal arterial anatomy and its variation across the patient population when minimally invasively accessing a renal artery.
In addition to complicating renal arterial access, specifics of the renal anatomy also complicate establishment of stable contact between neuromodulatory apparatus and a luminal surface or wall of a renal artery. For example, navigation can be impeded by the tight space within a renal artery, as well as tortuosity of the artery. Furthermore, establishing consistent contact is complicated by patient movement, respiration, and/or the cardiac cycle because these factors may cause significant movement of the renal artery relative to the aorta, and the cardiac cycle may transiently distend the renal artery (i.e. cause the wall of the artery to pulse).
Even after accessing a renal artery and facilitating stable contact between the neuromodulatory apparatus and a luminal surface of the artery, nerves in and around the adventitia of the artery should be safely modulated via the neuromodulatory apparatus. Effectively applying thermal treatment from within a renal artery is non-trivial given the potential clinical complications associated with such treatment. For example, the intima and media of the renal artery are highly vulnerable to thermal injury. As discussed in greater detail below, the intima-media thickness separating the vessel lumen from its adventitia means that target renal nerves may be multiple millimeters distant from the luminal surface of the artery. Sufficient energy should be delivered to or heat removed from the target renal nerves to modulate the target renal nerves without excessively cooling or heating the vessel wall to the extent that the wall is frozen, desiccated, or otherwise potentially affected to an undesirable extent. A potential clinical complication associated with excessive heating is thrombus formation from coagulating blood flowing through the artery. Given that this thrombus may cause a kidney infarct, thereby causing irreversible damage to the kidney, thermal treatment from within the renal artery should be applied carefully. Accordingly, the complex fluid mechanics and thermodynamic conditions present in the renal artery during treatment, particularly those that may impact heat transfer dynamics at the treatment region, may be important in applying energy (e.g., heating thermal energy) and/or removing heat from the tissue (e.g., cooling thermal conditions) from within the renal artery.
The neuromodulatory apparatus should also be configured to allow for adjustable positioning and repositioning of the energy delivery element within the renal artery since location of treatment may also impact clinical efficacy. For example, it may be tempting to apply a full circumferential treatment from within the renal artery given that the renal nerves may be spaced circumferentially around a renal artery. In some situations, a full-circle lesion likely resulting from a continuous circumferential treatment may be potentially related to renal artery stenosis. Therefore, the formation of more complex lesions along a longitudinal dimension of the renal artery and/or repositioning of the neuromodulatory apparatus to multiple treatment locations may be desirable. It should be noted, however, that a benefit of creating a circumferential ablation may outweigh the potential of renal artery stenosis or the risk may be mitigated with certain embodiments or in certain patients and creating a circumferential ablation could be a goal. Additionally, variable positioning and repositioning of the neuromodulatory apparatus may prove to be useful in circumstances where the renal artery is particularly tortuous or where there are proximal branch vessels off the renal artery main vessel, making treatment in certain locations challenging. Manipulation of a device in a renal artery should also consider mechanical injury imposed by the device on the renal artery. Motion of a device in an artery, for example by inserting, manipulating, negotiating bends and so forth, may contribute to dissection, perforation, denuding intima, or disrupting the interior elastic lamina.
The following examples are illustrative of several embodiments of the present technology:
1. A method for evaluating a vessel for neuromodulation therapy, the method comprising:
2. The method of example 1 wherein receiving the three-dimensional imaging data includes receiving three-dimensional imaging data of a renal artery, a pulmonary artery, a hepatic artery, a coronary artery, or an aorta.
3. The method of examples 1 or 2 wherein receiving the three-dimensional imaging data of the vessel includes receiving three-dimensional imaging data of a main vessel, at least one branch vessel of the main vessel, or at least one accessory vessel directly coupled to the at least one of the branch vessel or another vessel coupled to the main vessel.
4. The method of any one of examples 1-3, further comprising:
5. The method of any one of examples 1-4 wherein providing the recommendation via the processor comprises generating a signal to the user indicative of the avoidance regions, wherein the signal includes an audio signal, a visual signal, a tactile signal, or a combination thereof.
6. The method of any one of examples 1-5 wherein displaying the representation of the vessel further comprises displaying indicators of optimal portions or acceptable portions of the vessel for delivering neuromodulation therapy.
7. The method of any one of examples 1-6 wherein displaying the representation of the vessel further comprises:
8. The method of any one of examples 1-7 wherein receiving the hemodynamic data comprises receiving blood pressure data, blood flow data, blood impedance data, or a combination thereof.
9. The method of any one of examples 1-8 wherein receiving the hemodynamic data comprises receiving the pressure data and/or blood flow data via a guidewire having a pressure sensor and/or a flow sensor.
10. The method of any one of examples 1-9 wherein receiving the hemodynamic data comprises:
receiving blood pressure data via an external pressure cuff; and/or
11. The method of any one of examples 1-10 wherein receiving the digital data regarding three-dimensional imaging of the vessel comprises receiving data acquired using angiography, x-ray, computed tomography (CT), MRI, or a combination thereof.
12. The method of any one of examples 1-11 wherein receiving hemodynamic data comprises receiving blood pressure data and/or blood flow data measured at a position within a main portion of the vessel having at least generally laminar flow.
13. The method of any one of examples 1-12 wherein receiving hemodynamic data comprises receiving blood pressure data and/or blood flow data measured at a position within at least one branch vessel and/or at least one accessory vessel.
14. The method of any one of examples 1-13 wherein providing the recommendation further comprises:
15. The method of any one of examples 1-14 wherein identifying avoidance regions of the vessel comprises identifying portions of the vessel at or proximate to an ostium, a carina, a taper region, a calcification, a fibromuscular dysplasia, an aneurysm, a bifurcation, or a combination thereof.
16. The method of any one of examples 1-15 wherein generating the computational fluid dynamic model of the vessel comprises applying a hemodynamic parameter derived from empirical data or conglomerate data.
17. A method of identifying a target neuromodulation therapy region in a vessel of a human patient, the method comprising:
18. The method of example 17, further comprising:
19. The method of example 17 or 18, further comprising providing, via the user interface, a recommendation, made by the processor, of whether to proceed with neuromodulation therapy at the current neuromodulation catheter location within the vessel, the recommendation being based on a comparison between the current location of the neuromodulation catheter and the identified target regions and/or the identified avoidance regions of the vessel.
20. The method of any one of examples 17-19 wherein the location of the neuromodulation catheter is monitored in real-time.
21. The method of any one of examples 17-20 wherein receiving the hemodynamic data related to the vessel comprises detecting at least one of blood pressure or blood flow using a sensor disposed within the vessel.
22. The method of any one of examples 17-21 wherein identifying the avoidance regions comprises identifying portions of the vessel having low wall shear stress (WSS), high WSS, high WSS gradients, an ostium, a carina, a taper region, a calcification, a fibromuscular dysplasia, an aneurysm, a bifurcation, a region of blood flow separation, an eddy, a region of impinged blood flow, a region of turbulent blood flow, a region of secondary blood flow, or a combination thereof.
23. The method of any one of examples 17-22, further comprising applying neuromodulation energy to at least one of the identified target regions of the vessel, wherein the neuromodulation therapy comprises energy delivery, cryotherapy and/or chemical-based treatment.
24. The method of any one of examples 17-23 wherein receiving hemodynamic data related to the vessel comprises receiving at least one of a blood pressure measurement or a blood flow measurement from a sensor of the neuromodulation catheter.
25. A non-transitory computer readable memory storing instructions that, when executed by a processor of a computing device, cause the computing device to perform operations for identifying a target neuromodulation therapy region in a blood vessel, the operations comprising:
26. A system for optimizing neuromodulation therapy in a renal blood vessel of a human patient, the system comprising:
27. The system of example 26 wherein the sensor comprises at least one of a blood pressure sensor or a blood flow sensor.
28. The system of example 26 or 27 wherein the neuromodulation catheter further comprises a transmitter at the distal portion of the shaft, wherein the transmitter is configured to communicate, to a receiver, the current location of the neuromodulation assembly in the vessel.
This disclosure is not intended to be exhaustive or to limit the present technology to the precise forms disclosed herein. Although specific embodiments are disclosed herein for illustrative purposes, various equivalent modifications are possible without deviating from the present technology, as those of ordinary skill in the relevant art will recognize. In some cases, well-known structures and functions have not been shown and/or described in detail to avoid unnecessarily obscuring the description of the embodiments of the present technology. Although steps of methods may be presented herein in a particular order, in alternative embodiments the steps may have another suitable order. Similarly, certain aspects of the present technology disclosed in the context of particular embodiments can be combined or eliminated in other embodiments. For example, where a multi-electrode or multi-element neuromodulation catheter is shown herein, a single-electrode or single-element neuromodulation catheter may be used instead. Furthermore, while advantages associated with certain embodiments may have been disclosed in the context of those embodiments, other embodiments can also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages or other advantages disclosed herein to fall within the scope of the present technology. Accordingly, this disclosure and associated technology can encompass other embodiments not expressly shown and/or described herein.
Several implementations of the disclosed technology are described above in reference to the figures. The computing devices on which the described technology may be implemented can include one or more central processing units, memory, input devices (e.g., keyboard and pointing devices), output devices (e.g., display devices), storage devices (e.g., disk drives), and network devices (e.g., network interfaces). The memory and storage devices are computer-readable storage media that can store instructions that implement at least portions of the described technology. In addition, the data structures and message structures can be stored or transmitted via a data transmission medium, such as a signal on a communications link. Various communications links can be used, such as the Internet, a local area network, a wide area network, or a point-to-point dial-up connection. Thus, computer-readable media can comprise computer-readable storage media (e.g., “non-transitory” media) and computer-readable transmission media.
Throughout this disclosure, the singular terms “a,” “an,” and “the” include plural referents unless the context clearly indicates otherwise. Similarly, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the terms “comprising” and the like are used throughout this disclosure to mean including at least the recited feature(s) such that any greater number of the same feature(s) and/or one or more additional types of features are not precluded. Directional terms, such as “upper,” “lower,” “front,” “back,” “vertical,” and “horizontal,” may be used herein to express and clarify the relationship between various elements. It should be understood that such terms do not denote absolute orientation. Reference herein to “one embodiment,” “an embodiment,” or similar formulations means that a particular feature, structure, operation, or characteristic described in connection with the embodiment can be included in at least one embodiment of the present technology. Thus, the appearances of such phrases or formulations herein are not necessarily all referring to the same embodiment. Furthermore, various particular features, structures, operations, or characteristics may be combined in any suitable manner in one or more embodiments.
This application is a Continuation of U.S. Patent Application No. 15/337,742, filed Oct. 28, 2016, now U.S. Pat. No. 10,231,784, the disclosure of which is incorporated herein by reference in its entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4602624 | Naples et al. | Jul 1986 | A |
| 4649936 | Ungar et al. | Mar 1987 | A |
| 4709698 | Johnston et al. | Dec 1987 | A |
| 4764504 | Johnson et al. | Aug 1988 | A |
| 4890623 | Cook et al. | Jan 1990 | A |
| 4976711 | Parins et al. | Dec 1990 | A |
| 5300068 | Rosar et al. | Apr 1994 | A |
| 5301683 | Durkan | Apr 1994 | A |
| 5358514 | Schulman et al. | Oct 1994 | A |
| 5368591 | Lennox et al. | Nov 1994 | A |
| 5423744 | Gencheff et al. | Jun 1995 | A |
| 5484400 | Edwards et al. | Jan 1996 | A |
| 5571147 | Sluijter et al. | Nov 1996 | A |
| 5588964 | Imran et al. | Dec 1996 | A |
| 5599345 | Edwards et al. | Feb 1997 | A |
| 5626576 | Janssen | May 1997 | A |
| 5672174 | Gough et al. | Sep 1997 | A |
| 5688266 | Edwards et al. | Nov 1997 | A |
| 5700282 | Zabara | Dec 1997 | A |
| 5707400 | Terry, Jr. et al. | Jan 1998 | A |
| 5772590 | Webster, Jr. | Jun 1998 | A |
| 5860974 | Abele | Jan 1999 | A |
| 5865787 | Shapland | Feb 1999 | A |
| 5893885 | Webster, Jr. | Apr 1999 | A |
| 5944710 | Dev et al. | Aug 1999 | A |
| 5954719 | Chen et al. | Sep 1999 | A |
| 5983141 | Sluijter et al. | Nov 1999 | A |
| 6004269 | Crowley et al. | Dec 1999 | A |
| 6009877 | Edwards | Jan 2000 | A |
| 6024740 | Lesh et al. | Feb 2000 | A |
| 6036687 | Laufer et al. | Mar 2000 | A |
| 6066134 | Eggers et al. | May 2000 | A |
| 6091995 | Ingle et al. | Jul 2000 | A |
| 6099524 | Lipson et al. | Aug 2000 | A |
| 6117101 | Diederich et al. | Sep 2000 | A |
| 6135999 | Fanton et al. | Oct 2000 | A |
| 6142993 | Whayne et al. | Nov 2000 | A |
| 6149620 | Baker et al. | Nov 2000 | A |
| 6161048 | Sluijter et al. | Dec 2000 | A |
| 6219577 | Brown, III et al. | Apr 2001 | B1 |
| 6224592 | Eggers et al. | May 2001 | B1 |
| 6246912 | Sluijter et al. | Jun 2001 | B1 |
| 6273886 | Edwards et al. | Aug 2001 | B1 |
| 6283951 | Flaherty et al. | Sep 2001 | B1 |
| 6292695 | Webster, Jr. et al. | Sep 2001 | B1 |
| 6314325 | Fitz | Nov 2001 | B1 |
| 6322558 | Taylor et al. | Nov 2001 | B1 |
| 6322559 | Daulton et al. | Nov 2001 | B1 |
| 6405732 | Edwards et al. | Jun 2002 | B1 |
| 6413255 | Stern | Jul 2002 | B1 |
| 6488679 | Swanson et al. | Dec 2002 | B1 |
| 6506189 | Rittman et al. | Jan 2003 | B1 |
| 6514226 | Levin et al. | Feb 2003 | B1 |
| 6522926 | Kieval et al. | Feb 2003 | B1 |
| 6542781 | Koblish et al. | Apr 2003 | B1 |
| 6562034 | Edwards et al. | May 2003 | B2 |
| 6616624 | Kieval | Sep 2003 | B1 |
| 6622731 | Daniel et al. | Sep 2003 | B2 |
| 6635054 | Fjield et al. | Oct 2003 | B2 |
| 6640120 | Swanson et al. | Oct 2003 | B1 |
| 6685648 | Flaherty et al. | Feb 2004 | B2 |
| 6711433 | Geiger et al. | Mar 2004 | B1 |
| 6711444 | Koblish | Mar 2004 | B2 |
| 6736835 | Pellegrino et al. | May 2004 | B2 |
| 6752805 | Maguire et al. | Jun 2004 | B2 |
| 6845267 | Harrison et al. | Jan 2005 | B2 |
| 6850801 | Kieval et al. | Feb 2005 | B2 |
| 6869431 | Maguire et al. | Mar 2005 | B2 |
| 6885888 | Rezai | Apr 2005 | B2 |
| 6893436 | Woodard et al. | May 2005 | B2 |
| 6917834 | Koblish et al. | Jul 2005 | B2 |
| 6923808 | Taimisto | Aug 2005 | B2 |
| 6939346 | Kannenberg et al. | Sep 2005 | B2 |
| 6949097 | Stewart et al. | Sep 2005 | B2 |
| 7149574 | Yun et al. | Dec 2006 | B2 |
| 7160296 | Pearson et al. | Jan 2007 | B2 |
| 7162303 | Levin et al. | Jan 2007 | B2 |
| 7221979 | Zhou et al. | May 2007 | B2 |
| 7381200 | Katoh et al. | Jun 2008 | B2 |
| 7390894 | Weinshilboum et al. | Jun 2008 | B2 |
| 7617005 | Demarais et al. | Nov 2009 | B2 |
| 7620451 | Demarais et al. | Nov 2009 | B2 |
| 7647115 | Levin et al. | Jan 2010 | B2 |
| 7653438 | Deem et al. | Jan 2010 | B2 |
| 7717948 | Demarais et al. | May 2010 | B2 |
| 7778703 | Gross et al. | Aug 2010 | B2 |
| 8131371 | Demarais et al. | Mar 2012 | B2 |
| 8131372 | Levin et al. | Mar 2012 | B2 |
| 8140170 | Rezai et al. | Mar 2012 | B2 |
| 8145317 | Demarais et al. | Mar 2012 | B2 |
| 8150518 | Levin et al. | Apr 2012 | B2 |
| 8150519 | Demarais et al. | Apr 2012 | B2 |
| 8150520 | Demarais et al. | Apr 2012 | B2 |
| 8175711 | Demarais et al. | May 2012 | B2 |
| 8702619 | Wang | Apr 2014 | B2 |
| 8768470 | Deem et al. | Jul 2014 | B2 |
| 8777942 | Wu et al. | Jul 2014 | B2 |
| 8888773 | Chang et al. | Nov 2014 | B2 |
| 8909316 | Ng | Dec 2014 | B2 |
| 8977359 | Rossing | Mar 2015 | B2 |
| 8998894 | Mauch et al. | Apr 2015 | B2 |
| 9002446 | Wenzel et al. | Apr 2015 | B2 |
| 9014809 | Wenzel et al. | Apr 2015 | B2 |
| 9014821 | Wang | Apr 2015 | B2 |
| 9022948 | Wang | May 2015 | B2 |
| 9043191 | Grady et al. | May 2015 | B2 |
| 9060755 | Buckley et al. | Jul 2015 | B2 |
| 9084610 | Goshgarian et al. | Jul 2015 | B2 |
| 9119600 | Richardson et al. | Sep 2015 | B2 |
| 9168094 | Lee et al. | Oct 2015 | B2 |
| 9179973 | Nabutovsky et al. | Nov 2015 | B2 |
| 9186212 | Nabutovsky et al. | Nov 2015 | B2 |
| 9295842 | Ghaffari et al. | Mar 2016 | B2 |
| 9314300 | Nabutovsky et al. | Apr 2016 | B2 |
| 9327123 | Yamasaki et al. | May 2016 | B2 |
| 9375154 | Wang | Jun 2016 | B2 |
| 9427283 | Nabutovsky et al. | Aug 2016 | B2 |
| 9427579 | Fain et al. | Aug 2016 | B2 |
| 9554850 | Lee et al. | Jan 2017 | B2 |
| 9579030 | Scheuermann et al. | Feb 2017 | B2 |
| 10231784 | Hettrick et al. | Mar 2019 | B2 |
| 10939822 | Ben-Haim et al. | Mar 2021 | B2 |
| 20020087208 | Koblish et al. | Jul 2002 | A1 |
| 20020107515 | Edwards et al. | Aug 2002 | A1 |
| 20020139379 | Edwards et al. | Oct 2002 | A1 |
| 20020165532 | Hill, III et al. | Nov 2002 | A1 |
| 20020183682 | Darvish et al. | Dec 2002 | A1 |
| 20030050635 | Truckai et al. | Mar 2003 | A1 |
| 20030050681 | Pianca et al. | Mar 2003 | A1 |
| 20030060858 | Kieval et al. | Mar 2003 | A1 |
| 20030074039 | Puskas | Apr 2003 | A1 |
| 20030125790 | Fastovsky et al. | Jul 2003 | A1 |
| 20030181897 | Thomas et al. | Sep 2003 | A1 |
| 20030195507 | Stewart et al. | Oct 2003 | A1 |
| 20030199863 | Swanson et al. | Oct 2003 | A1 |
| 20030216792 | Levin et al. | Nov 2003 | A1 |
| 20030229340 | Sherry et al. | Dec 2003 | A1 |
| 20030233099 | Danaek et al. | Dec 2003 | A1 |
| 20040010289 | Biggs et al. | Jan 2004 | A1 |
| 20040167509 | Taimisto | Aug 2004 | A1 |
| 20040215186 | Cornelius et al. | Oct 2004 | A1 |
| 20050080409 | Young et al. | Apr 2005 | A1 |
| 20050096647 | Steinke et al. | May 2005 | A1 |
| 20050187579 | Danek et al. | Aug 2005 | A1 |
| 20050228460 | Levin et al. | Oct 2005 | A1 |
| 20060085054 | Zikorus et al. | Apr 2006 | A1 |
| 20060095029 | Young et al. | May 2006 | A1 |
| 20060206150 | Demarais et al. | Sep 2006 | A1 |
| 20060212076 | Demarais et al. | Sep 2006 | A1 |
| 20060271111 | Demarais et al. | Nov 2006 | A1 |
| 20070129720 | Demarais et al. | Jun 2007 | A1 |
| 20070265687 | Deem et al. | Nov 2007 | A1 |
| 20080319513 | Pu et al. | Dec 2008 | A1 |
| 20090036948 | Levin et al. | Feb 2009 | A1 |
| 20090177089 | Govari et al. | Jul 2009 | A1 |
| 20100137860 | Demarais et al. | Jun 2010 | A1 |
| 20100137952 | Demarais et al. | Jun 2010 | A1 |
| 20100191112 | Demarais et al. | Jul 2010 | A1 |
| 20100222851 | Deem et al. | Sep 2010 | A1 |
| 20100222854 | Demarais et al. | Sep 2010 | A1 |
| 20110112400 | Emery | May 2011 | A1 |
| 20110270120 | McFarlin et al. | Nov 2011 | A1 |
| 20110306851 | Wang | Dec 2011 | A1 |
| 20120029504 | Afonso et al. | Feb 2012 | A1 |
| 20120116382 | Ku et al. | May 2012 | A1 |
| 20120123400 | Francischelli et al. | May 2012 | A1 |
| 20120130289 | Demarais et al. | May 2012 | A1 |
| 20120130345 | Levin et al. | May 2012 | A1 |
| 20120143097 | Pike, Jr. | Jun 2012 | A1 |
| 20120172837 | Demarais et al. | Jun 2012 | A1 |
| 20120172870 | Jenson et al. | Jul 2012 | A1 |
| 20120191079 | Moll et al. | Jul 2012 | A1 |
| 20120296232 | Ng | Nov 2012 | A1 |
| 20120296329 | Ng | Nov 2012 | A1 |
| 20130085489 | Fain et al. | Apr 2013 | A1 |
| 20130123778 | Richardson et al. | May 2013 | A1 |
| 20130165764 | Scheuermann et al. | Jun 2013 | A1 |
| 20130172878 | Subramaniam et al. | Jul 2013 | A1 |
| 20130218029 | Cholette et al. | Aug 2013 | A1 |
| 20130274614 | Shimada et al. | Oct 2013 | A1 |
| 20130282001 | Hezi-Yamit et al. | Oct 2013 | A1 |
| 20140005535 | Edic et al. | Jan 2014 | A1 |
| 20140012133 | Sverdlik et al. | Jan 2014 | A1 |
| 20140012242 | Lee et al. | Jan 2014 | A1 |
| 20140066803 | Choi | Mar 2014 | A1 |
| 20140073903 | Weber et al. | Mar 2014 | A1 |
| 20140074089 | Nishii | Mar 2014 | A1 |
| 20140128865 | Gross | May 2014 | A1 |
| 20140194866 | Wang | Jul 2014 | A1 |
| 20140213873 | Wang | Jul 2014 | A1 |
| 20140221805 | Wang | Aug 2014 | A1 |
| 20140236011 | Fan | Aug 2014 | A1 |
| 20140236137 | Binh et al. | Aug 2014 | A1 |
| 20140236138 | Tran et al. | Aug 2014 | A1 |
| 20140246465 | Peterson et al. | Sep 2014 | A1 |
| 20140249524 | Kocur | Sep 2014 | A1 |
| 20140266235 | Mathur | Sep 2014 | A1 |
| 20140275924 | Min et al. | Sep 2014 | A1 |
| 20140276124 | Cholette et al. | Sep 2014 | A1 |
| 20140276733 | VanScoy et al. | Sep 2014 | A1 |
| 20140276742 | Nabutovsky et al. | Sep 2014 | A1 |
| 20140276746 | Nabutovsky et al. | Sep 2014 | A1 |
| 20140276755 | Cao et al. | Sep 2014 | A1 |
| 20140276762 | Parsonage | Sep 2014 | A1 |
| 20140276766 | Brotz et al. | Sep 2014 | A1 |
| 20140276767 | Brotz et al. | Sep 2014 | A1 |
| 20140276773 | Brotz et al. | Sep 2014 | A1 |
| 20140316400 | Blix et al. | Oct 2014 | A1 |
| 20140316496 | Masson et al. | Oct 2014 | A1 |
| 20140330267 | Harrington | Nov 2014 | A1 |
| 20140336637 | Agrawal et al. | Nov 2014 | A1 |
| 20150005764 | Hanson et al. | Jan 2015 | A1 |
| 20150018656 | Min et al. | Jan 2015 | A1 |
| 20150025524 | Nabutovsky | Jan 2015 | A1 |
| 20150112329 | Ng | Apr 2015 | A1 |
| 20150119674 | Fischell et al. | Apr 2015 | A1 |
| 20150173673 | Toth et al. | Jun 2015 | A1 |
| 20150201997 | Osypka | Jul 2015 | A1 |
| 20150216590 | Wang et al. | Aug 2015 | A1 |
| 20150223877 | Behar et al. | Aug 2015 | A1 |
| 20150224326 | Toth et al. | Aug 2015 | A1 |
| 20150242588 | Audigier | Aug 2015 | A1 |
| 20150289770 | Wang | Oct 2015 | A1 |
| 20150289929 | Toth et al. | Oct 2015 | A1 |
| 20150366609 | Richardson et al. | Dec 2015 | A1 |
| 20160000345 | Kobayashi et al. | Jan 2016 | A1 |
| 20160015452 | Nabutovsky et al. | Jan 2016 | A1 |
| 20160029960 | Toth et al. | Feb 2016 | A1 |
| 20160038028 | Buelna et al. | Feb 2016 | A1 |
| 20160081744 | Wang | Mar 2016 | A1 |
| 20160095652 | Lee et al. | Apr 2016 | A1 |
| 20160106498 | Highsmith et al. | Apr 2016 | A1 |
| 20160184010 | Nabutovsky et al. | Jun 2016 | A1 |
| 20160213262 | Ghaffari et al. | Jul 2016 | A1 |
| 20160213424 | Ghaffari et al. | Jul 2016 | A1 |
| 20160302857 | Rothman et al. | Oct 2016 | A1 |
| 20160324572 | Gross et al. | Nov 2016 | A1 |
| 20160331451 | Nabutovsky et al. | Nov 2016 | A1 |
| 20160331453 | Fain et al. | Nov 2016 | A1 |
| 20160374568 | Wang | Dec 2016 | A1 |
| Number | Date | Country |
|---|---|---|
| 101548897 | Oct 2009 | CN |
| 104936511 | Sep 2015 | CN |
| 1169976 | Jan 2002 | EP |
| 2316371 | May 2011 | EP |
| 2594193 | May 2013 | EP |
| 2613704 | Jul 2013 | EP |
| 2747691 | Jul 2014 | EP |
| 2797535 | Nov 2014 | EP |
| 2852339 | Apr 2015 | EP |
| 2866645 | May 2015 | EP |
| 2887900 | Jul 2015 | EP |
| 2907464 | Aug 2015 | EP |
| 2914334 | Sep 2015 | EP |
| 2967383 | Jan 2016 | EP |
| 2978372 | Feb 2016 | EP |
| 3011899 | Apr 2016 | EP |
| 3028628 | Jun 2016 | EP |
| 3089686 | Nov 2016 | EP |
| 2709517 | Jan 2017 | EP |
| H08504531 | May 1996 | JP |
| H1071037 | Mar 1998 | JP |
| 2001518808 | Oct 2001 | JP |
| 2005278739 | Oct 2005 | JP |
| 2008515544 | May 2008 | JP |
| 2009539565 | Nov 2009 | JP |
| 2010162163 | Jul 2010 | JP |
| 2010533513 | Oct 2010 | JP |
| 2011505929 | Mar 2011 | JP |
| 2015073691 | Apr 2015 | JP |
| WO2014091328 | Jul 1989 | WO |
| WO1994007446 | Apr 1994 | WO |
| WO1995025472 | Sep 1995 | WO |
| WO1995031142 | Nov 1995 | WO |
| WO1997036548 | Oct 1997 | WO |
| WO1998042403 | Oct 1998 | WO |
| WO1999000060 | Jan 1999 | WO |
| WO2001022897 | Apr 2001 | WO |
| WO2001070114 | Sep 2001 | WO |
| WO2003022167 | Mar 2003 | WO |
| WO2003082080 | Oct 2003 | WO |
| WO2005030072 | Apr 2005 | WO |
| WO2005041748 | May 2005 | WO |
| WO2005110528 | Nov 2005 | WO |
| WO2006041881 | Apr 2006 | WO |
| WO2006105121 | Oct 2006 | WO |
| WO2007008954 | Jan 2007 | WO |
| WO2007078997 | Jul 2007 | WO |
| WO2008003058 | Jan 2008 | WO |
| WO2008049084 | Apr 2008 | WO |
| WO2010078175 | Jul 2010 | WO |
| WO2011089935 | Jul 2011 | WO |
| WO2012033974 | Mar 2012 | WO |
| 2012061159 | May 2012 | WO |
| WO2012061159 | May 2012 | WO |
| WO2012068471 | May 2012 | WO |
| WO2012158864 | Nov 2012 | WO |
| WO2013030738 | Mar 2013 | WO |
| WO2013030743 | Mar 2013 | WO |
| WO2013074813 | May 2013 | WO |
| WO2013101485 | Jul 2013 | WO |
| WO2013112844 | Aug 2013 | WO |
| WO2014012282 | Jan 2014 | WO |
| WO2014029355 | Feb 2014 | WO |
| WO2014059165 | Apr 2014 | WO |
| WO2014068577 | May 2014 | WO |
| WO2014068606 | May 2014 | WO |
| WO2014091401 | Jun 2014 | WO |
| WO2014149550 | Sep 2014 | WO |
| WO2014149552 | Sep 2014 | WO |
| WO2014149553 | Sep 2014 | WO |
| WO2014149690 | Sep 2014 | WO |
| WO2014150425 | Sep 2014 | WO |
| WO2014150432 | Sep 2014 | WO |
| WO2014150441 | Sep 2014 | WO |
| WO2014150455 | Sep 2014 | WO |
| WO2014158708 | Oct 2014 | WO |
| WO2014158713 | Oct 2014 | WO |
| WO2014163990 | Oct 2014 | WO |
| WO2014179768 | Nov 2014 | WO |
| WO2014182946 | Nov 2014 | WO |
| 2016054379 | Apr 2016 | WO |
| 2016100720 | Jun 2016 | WO |
| WO2016100720 | Jun 2016 | WO |
| Entry |
|---|
| First Examiner Report, dated Jul. 29, 2019, in Australian Application No. 2017348332. |
| International Preliminary Report on Patentability from International Application No. PCT/US2017/058731, dated May 9, 2019, 12 pp. |
| Response to First Examination Report dated Jul. 29, 2019 from counterpart Australian Patent Application No. 2017348332, dated Oct. 11, 2019, 25 pp. |
| Notice of Acceptance from counterpart Australian Patent Application No. 2017348332, dated Nov. 12, 2019, 3 pp. |
| Response to Communication Pursuant to Rules 161(1) and 162 EPC dated Jun. 5, 2019, from counterpart European Application No. 17801154.0, filed Nov. 26, 2019, 21 pp. |
| Mark R. de Jong et al. “Renal Nerve Stimulation-Induced Blood Pressure Changes Predict Ambulatory Blood Pressure Response After Renal Denervation” Mar. 9, 2016, Hypertension 2016; 68:707-714. |
| Allen, E.V., Sympathectomy for essential hypertension, Circulation, 1952, 6:131-140. |
| Bello-Reuss, E. et al., “Effects of Acute Unilateral Renal Denervation in the Rat,” Journal of Clinical Investigation, vol. 56, Jul. 1975, pp. 208-217. |
| Bello-Reuss, E. et al., “Effects of Renal Sympathetic Nerve Stimulation on Proximal Water and Sodium Reabsorption,” Journal of Clinical Investigation, vol. 57, Apr. 1976, pp. 1104-1107. |
| Bhandari, A. and Ellias, M., “Loin Pain Hematuria Syndrome: Pain Control with RFA to the Splanchanic Plexus,” The Pain Clinc, 2000, vol. 12, No. 4, pp. 323-327. |
| Curtis, John J. et al., “Surgical Therapy for Persistent Hypertension After Renal Transplantation” Transplantation, 31:125-128 (1981). |
| Dibona, Gerald F. et al., “Neural Control of Renal Function,” Physiological Reviews, vol. 77, No. 1, Jan. 1997, The American Physiological Society 1997, pp. 75-197. |
| Dibona, Gerald F., “Neural Control of the Kidney- Past, Present and Future,” Nov. 4, 2002, Novartis Lecture, Hypertension 2003, 41 part 2, 2002 American Heart Association, Inc., pp. 621-624. |
| Janssen, Ben J.A. et al., “Effects of Complete Renal Denervation and Selective Afferent Renal Denervation on the Hypertension Induced by Intrarenal Norepinephrine Infusion in Conscious Rats”, Journal of Hypertension 1989, 7: 447-455. |
| Katholi, Richard E., “Renal Nerves in the Pathogenesis of Hypertension in Experimental Animals and Humans,” Am J. Physiol. vol. 245, 1983, the American Physiological Society 1983, pp. F1-F14. |
| Krum, Henry et al., “Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Mulitcentre Safety and Proof-of Principle Cohort Study,” Lancet 2009; 373:1275-81. |
| Krum, et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension.” New England Journal of Med, Aug. 2009, 361; 9, 3 pages. |
| Luippold, Gerd et al., “Chronic Renal Denervation Prevents Glomerular Hyperfiltration in Diabetic Rats”, Nephrol Dial Transplant, vol. 19, No. 2, 2004, pp. 342-347. |
| Mahfoud et al. “Treatment strategies for resistant arterial hypertension” Dtsch Arztebl Int. 2011;108:725-731. |
| Osborn, et al., “Effect of Renal Nerve Stimulation on Renal Blood Flow Autoregulation and Antinatriuresis During Reductions in Renal Perfusion Pressure,” Proceedings of the Society for Experimental Biology and Medicine, vol. 168, 77-81, 1981. |
| Page, I.H. et al., “The Effect of Renal Denervation on Patients Suffering From Nephritis,” Feb. 27, 1935;443-458. |
| Page, I.H et al., “The Effect of Renal Denervation on the Level of Arterial Blood Pressure and Renal Function in Essential Hypertension,” J. Clin Invest. 1934;14:27-30. |
| Rocha-Singh, “Catheter-Based Sympathetic Renal Denervation,” Endovascular Today, Aug. 2009, 4 pages. |
| Schlaich, M.P. et al., “Renal Denervation as a Therapeutic Approach for Hypertension: Novel Implications for an Old Concept,” Hypertension, 2009; 54:1195-1201. |
| Schlaich, M.P. et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension,” N Engl J Med 2009; 361(9): 932-934. |
| Smithwick, R.H. et al., “Splanchnicectomy for Essential Hypertension,” Journal Am Med Assn, 1953; 152:1501-1504. |
| Symplicity HTN-1 Investigators; Krum H, Barman N, Schlaich M, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-917. |
| Symplicity HTN-2 Investigators, “Renal Sympathetic Denervation in Patients with Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial): A Randomised Controlled Trial”; Lancet, Dec. 4, 2010, vol. 376, pp. 1903-1909. |
| United States Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003, 593 pages. |
| Valente, John F. et al., “Laparoscopic Renal Denervation for Intractable ADPKD-Related Pain”, Nephrol Dial Transplant (2001) 16: 1 page. |
| Wagner, C.D. et al., “Very Low Frequency Oscillations in Arterial Blood Pressure After Autonomic Blockade in Conscious Dogs,” Feb. 5, 1997, Am J Physiol Regul Integr Comp Physiol 1997, vol. 272, 1997 the American Physiological Society, pp. 2034-2039. |
| Ahmed, Humera et al., Renal Sympathetic Denervation Using an Irrigated Radiofrequency Ablation Catheter for the Management of Drug-Resistant Hypertension, JACC Cardiovascular Interventions, vol. 5, No. 7, 2012, pp. 758-765. |
| Avitall et al., “The creation of linear contiguous lesions in the atria with an expandable loop catheter,” Journal of the American College of Cardiology, 1999; 33; pp. 972-984. |
| Beale et al., “Minimally Invasive Treatment for Varicose Veins: A Review of Endovenous Laser Treatment and Radiofrequency Ablation”. Lower Extremity Wounds 3(4), 2004, 10 pages. |
| Blessing, Erwin et al., Cardiac Ablation and Renal Denervation Systems Have Distinct Purposes and Different Technical Requirements, JACC Cardiovascular Interventions, vol. 6, No. 3, 2013, 1 page. |
| Clinicaltrials.Gov, Renal Denervation in Patients with uncontrolled Hypertension in Chinese (2011), 6pages. www.clinicaltrials.gov/ct2/show/NCT01390831. |
| Dodge, et al., “Lumen Diameter of Normal Human Coronary Arteries Influence of Age, Sex, Anatomic Variation, and Left Ventricular Hypertrophy or Dilation”, Circulation, 1992, vol. 86 (1), pp. 232-246. |
| Excerpt of Operator's Manual of Boston Scientific's EPT-1000 XP Cardiac Ablation Controller & Accessories, Version of Apr. 2003, (6 pages). |
| Excerpt of Operator's Manual of Boston Scientific's Maestro 30000 Cardiac Ablation System, Version of Oct. 17, 2005 , (4 pages). |
| Holmes et al., Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation: Clinical Spectrum and Interventional Considerations, JACC: Cardiovascular Interventions, 2: 4, 2009, 10 pages. |
| Kandarpa, Krishna et al., “Handbook of Interventional Radiologic Procedures”, Third Edition, pp. 194-210 (2002). |
| Mount Sinai School of Medicine clinical trial for Impact of Renal Sympathetic Denervation of Chronic Hypertension, Mar. 2013, 11 pages. http://clinicaltrials.gov/ct2/show/NCT01628198. |
| Opposition to European Patent No. 2465470, Granted Oct. 28, 2015, Date of Opposition Jul. 27, 2016, 34 pp. |
| Opposition to European Patent No. EP1802370, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 20 pages. |
| Opposition to European Patent No. EP2037840, Granted Dec. 7, 2011, Date of Opposition Sep. 7, 2012, 25 pages. |
| Opposition to European Patent No. EP2092957, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 26 pages. |
| Oz, Mehmet, Pressure Relief, TIME, Jan. 9, 2012, 2 pages. <www.time.come/time/printout/0,8816,2103278,00.html>. |
| Papademetriou, Vasilios, Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension, Int. Journal of Hypertension, 2011, 8 pages. |
| Pieper, et al., “Design and Implementation of a New Computerized System for Intraoperative Cardiac Mapping” Journal of Applied Physiology, 1991, vol. 71 (4), pp. 1529-1539. |
| Prochnau, Dirk et al., Catheter-based renal denervation fordrug-resistant hypertension by using a standard electrophysiology catheter; Euro Intervention 2012, vol. 7, pp. 1077-1080. |
| Purerfellner, Helmut et al., Incidence, Management, and Outcome in Significant Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation, Am. J. Cardiol, 93, Jun. 1, 2004, 4 pages. |
| Purerfellner, Helmut et al., Pulmonary Vein Stenosis Following Catheter Ablation of Atrial Fibrillation, Curr. Opin. Cardio. 20 :484-490, 2005. |
| Remo, et al., “Safety and Efficacy of Renal Denervation as a Novel Treatment of Ventricular Tachycardia Storm in Patients with Cardiomyopathy” Heart Rhythm, 2014, 11(4), pp. 541-546. |
| Schneider, Peter A., “Endovascular Skills—Guidewire and Catheter Skills for Endovascular Surgery,” Second Edition Revised and Expanded, 10 pages, (2003). |
| ThermoCool Irrigated Catheter and Integrated Ablation System, Biosense Webster (2006), 6 pages. |
| Tsao, Hsuan-Ming, Evaluation of Pulmonary Vein Stenosis after Catheter Ablation of Atrial Fibrillation, Cardiac Electrophysiology Review, 6, 2002, 4 pages. |
| U.S. Appl. No. 11/363,867, filed Feb. 27, 2006, 70 pp. |
| U.S. Appl. No. 60/813,589, filed Dec. 29, 2005, 62 pgs. |
| U.S. Appl. No. 60/852,787, filed Oct. 18, 2006, 112 pgs. |
| Ureter, https://en.wikipedia.org/wiki/Ureter, Jun. 2016, 6 pgs. |
| Wittkampf et al., “Control of radiofrequency lesion size by power regulation,” Journal of the American Heart Associate, 1989, 80: pp. 962-968. |
| Zheng et al., “Comparison of the temperature profile and pathological effect at unipolar, bipolar and phased radiofrequency current configurations,” Journal of Interventional Cardiac Electrophysiology, 2001, pp. 401-410. |
| U.S. Appl. No. 95/002,110, filed Aug. 29, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,209, filed Sep. 13, 2012, Levin et al. |
| U.S. Appl. No. 95/002,233, filed Sep. 13, 2012, Levin et al. |
| U.S. Appl. No. 95/002,243, filed Sep. 13, 2012, Levin et al. |
| U.S. Appl. No. 95/002,253, filed Sep. 13, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,255, filed Sep. 13, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,292, filed Sep. 14, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,327, filed Sep. 14, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,335, filed Sep. 14, 2012, Demarais et al. |
| U.S. Appl. No. 95/002,336, filed Sep. 14, 2012, Levin et al. |
| U.S. Appl. No. 95/002,356, filed Sep. 14, 2012, Demarais et al. |
| “2011 Edison Award Winners.” Edison Awards: Honoring Innovations & Innovators, 2011, 6 pages, <http://www.edisonawards.com/BestNewProduct_2011.php>. |
| “2012 top 10 advances in heart disease and stroke research: American Heart Association/America Stroke Association Top 10 Research Report.” American Heart Association, Dec. 17, 2012, 5 pages, <http://newsroom.heart.org/news/2012-top-10-advances-in-heart-241901>. |
| “Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension.” PR Newswire, Jun. 3, 2010, 2 pages, <http://www.prnewswire.com/news-releases/ardianr-receives-2010-europcr-innovation-award-and-demonstrates-further-durability-of-renal-denervation-treatment-for-hypertension-95545014.html>. |
| “Boston Scientific to Acquire Vessix Vascular, Inc.: Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology.” Boston Scientific: Advancing science for life—Investor Relations, Nov. 8, 2012, 2 pages, <http://phx.corporate-ir.net/phoenix.zhtml?c=62272&p=irol-newsArticle&id=1756108>. |
| “Cleveland Clinic Unveils Top 10 Medical Innovations for 2012: Experts Predict Ten Emerging Technologies that will Shape Health Care Next Year.” Cleveland Clinic, Oct. 6, 2011, 2 pages, <http://my.clevelandclinic.org/media_relations/library/2011/2011-10-6-cleveland-clinic-unveils-top-10-medical-innovations-for-2012.aspx>. |
| “Does renal denervation represent a new treatment option for resistant hypertension?” Interventional News, Aug. 3, 2010, 2 pages, <http://www.cxvascular.com/in-latest-news/interventional-news--latest-news/does-renal-denervation-represent-a-new-treatment-option-for-resistant-hypertension>. |
| “Iberis—Renal Sympathetic Denervation System: Turning innovation into quality care.” [Brochure], Terumo Europe N.V., 2013, Europe, 3 pages. |
| “Neurotech Reports Announces Winners of Gold Electrode Awards.” Neurotech business report, 2009. 1 page, <http://www.neurotechreports.com/pages/goldelectrodes09.html>. |
| “Quick. Consistent. Controlled. OneShot renal Denervation System” [Brochure], Covidien: positive results for life, 2013, (n.l.), 4 pages. |
| “Renal Denervation Technology of Vessix Vascular, Inc. been acquired by Boston Scientific Corporation (BSX) to pay up to $425 Million.” Vessix Vascular Pharmaceutical Intelligence: A blog specializing in Pharmaceutical Intelligence and Analytics, Nov. 8, 2012, 21 pages, <http://pharmaceuticalintelligence.com/tag/vessix-vascular/>. |
| “The Edison Awards™” Edison Awards: Honoring Innovations & Innovators, 2013, 2 pages, <http://www.edisonawards.com/Awards.php>. |
| “The Future of Renal denervation for the Treatment of Resistant Hypertension.” St. Jude Medical, Inc., 2012, 12 pages. |
| “Vessix Renal Denervation System: So Advanced It's Simple.” [Brochure], Boston Scientific: Advancing science for life, 2013, 6 pages. |
| Asbell, Penny, “Conductive Keratoplasty For The Correction of Hyperopia.” Tr Am Ophth Soc, 2001, vol. 99, 10 pages. |
| Badoer, Emilio, “Cardiac afferents play the dominant role in renal nerve inhibition elicited by volume expansion in the rabbit.” Am J Physiol Regul Integr Comp Physiol, vol. 274, 1998, 7 pages. |
| Bengel, Frank, “Serial Assessment of Sympathetic Reinnervation After Orthotopic Heart Transplantation: A longitudinal Study Using PET and C-11 Hydroxyephedrine.” Circulation, vol. 99, 1999,7 pages. |
| Benito, F., et al. “Radiofrequency catheter ablation of accessory pathways in infants.” Heart, 78:160-162 (1997). |
| Bettmann, Michael, Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals From the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association, Circulation, vol. 97, 1998, 4 pages. |
| Bohm, Michael et al., “Rationale and design of a large registry on renal denervation: the Global SYMPLICITY registry.” EuroIntervention, vol. 9, 2013, 9 pages. |
| Brosky, John, “EuroPCR 2013: CE-approved devices line up for renal denervation approval.” Medical Device Daily, May 28, 2013, 3 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=83002>. |
| Davis, Mark et al., “Effectiveness of Renal Denervation Therapy for Resistant Hypertension.” Journal of the American College of Cardiology, vol. 62, No. 3, 2013, 11 pages. |
| Dubuc, M., et al., “Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter.” J Interv Cardiac Electrophysiol, 2:285-292 (1998). |
| Final Office Action; U.S. Appl. No. 12/827,700; dated Feb. 5, 2013, 61 pages. |
| Geisler, Benjamin et al., “Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension.” Journal of the American College of Cardiology, col. 60, No. 14, 2012, 7 pages. |
| Gelfand, M., et al., “Treatment of renal failure and hypertension.” U.S. Appl. No. 60/442,970, filed Jan. 29, 2003, 23 pages. |
| Gertner, Jon, “Meet The Tech Duo That's Revitalizing The Medical Device Industry.” Fast Company, Apr. 15, 2013, 6:00 AM, 17 pages, <http://www.fastcompany.com/3007845/meet-tech-duo-thats-revitalizing-medical-device-industry>. |
| Golwyn, D. H., Jr., et al. “Percutaneous Transcatheter Renal Ablation with Absolute Ethanol for Uncontrolled Hypertension or Nephrotic Syndrome: Results in 11 Patients with End-Stage Renal Disease.” JVIR, 8: 527-533 (1997). |
| Hall, W. H., et al. “Combined embolization and percutaneous radiofrequency ablation of a solid renal tumor.” Am. J. Roentgenol,174: 1592-1594 (2000). |
| Han, Y.-M, et al., “Renal artery embolization with diluted hot contrast medium: An experimental study.” J Vase Interv Radiol, 12: 862-868 (2001). |
| Hansen, J. M., et al. “The transplanted human kidney does not achieve functional reinnervation.” Clin. Sci, 87: 13-19 (1994). |
| Hendee, W. R. et al. “Use of Animals in Biomedical Research: The Challenge and Response.” American Medical Association White Paper (1988) 39 pages. |
| Hering, Dagmara et al., “Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.” EuroIntervention, vol. 9, 2013, 9 pages. |
| Imimdtanz, “Medtronic awarded industry's highest honor for renal denervation system.” The official blog of Medtronic Australasia, Nov. 12, 2012, 2 pages, <http://97waterlooroad.wordpress.com/2012/11/12/medtronic-awarded-industrys-highest-honour-for-renal-denervation-system/>. |
| Kaiser, Chris, AHA Lists Year's Big Advances in CV Research, medpage Today, Dec. 18, 2012, 4 pages, <http://www.medpagetoday.com/Cardiology/PCI/36509>. |
| Kompanowska, E., et al., “Early Effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow.” J Physiol, 531. 2:527-534 (2001). |
| Lee, S. J., et al. “Ultrasonic energy in endoscopic surgery.” Yonsei Med J, 40:545-549 (1999). |
| Linz, Dominik et al., “Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs.” Heart Rhythm, vol. 0, No. 0, 2013, 6 pages. |
| Lustgarten, D. L., et al., “Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias.” Progr Cardiovasc Dis, 41:481-498 (1999). |
| Mabin, Tom et al., “First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension.” EuroIntervention, vol. 8, 2012, 5 pages. |
| Mahfoud, Felix et al., “Ambulatory Blood Pressure Changes after Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Circulation, 2013, 25 pages. |
| Mahfoud, Felix et al., “Expert consensus document from the European Society of Cardiology on catheter-based renal denervation.” European Heart Journal, 2013, 9 pages. |
| Mahfoud, Felix et al., “Renal Hemodynamics and Renal Function After Catheter-Based Renal Sympathetic Denervation in Patients With Resistant Hypertension.” Hypertension, 2012, 6 pages. |
| Medical-Dictionary.com, Definition of “Animal Model,” http://medical-dictionary.com (search “Animal Model”), 2005, 1 page. |
| Medtronic, Inc., Annual Report (Form 10-K) (Jun. 28, 2011) 44 pages. |
| Millard, F. C., et al., “Renal Embolization for ablation of function in renal failure and hypertension.” Postgraduate Medical Journal, 65, 729-734, (1989). |
| Oliveira, V., et al., “Renal denervation normalizes pressure and baroreceptor reflex in high renin hypertension in conscious rats.” Hypertension, 19:II-17-II-21 (1992). |
| Ong, K. L., et al. “Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999-2004.” Hypertension, 49: 69-75 (2007) (originally published online Dec. 11, 2006). |
| Ormiston, John et al., “First-in-human use of the OneShot™ renal denervation system from Covidien.” EuroIntervention, vol. 8, 2013, 4 pages. |
| Ormiston, John et al., “Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial.” EuroIntervention, vol. 9, 2013, 5 pages. |
| Pedersen, Amanda, “TCT 2012: Renal denervation device makers play show and tell.” Medical Device Daily, Oct. 26, 2012, 2 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=80880>. |
| Peet, M., “Hypertension and its Surgical Treatment by bilateral supradiaphragmatic splanchnicectomy” Am J Surgery (1948) pp. 48-68. |
| Renal Denervation (RDN), Symplicity RDN System Common Q&A (2011), 4 pages, http://www.medtronic.com/rdn/mediakit/RDN%20FAQ.pdf. |
| Schlaich, Markus et al., “Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects.” Curr Hypertens Rep, vol. 14, 2012, 7 pages. |
| Schmid, Axel et al., “Does Renal Artery Supply Indicate Treatment Success of Renal Denervation.” Cardiovasc Intervent Radiol, vol. 36, 2013, 5 pages. |
| Schmieder, Roland E. et al., “Updated ESH position paper on interventional therapy of resistant hypertension.” EuroIntervention, vol. 9, 2013, 9 pages. |
| Sievert, Horst, “Novelty Award EuroPCR2010.” Euro PCR, 2010, 15 pages. |
| Stella, A., et al., “Effects of reversible renal denervation on haemodynamic and excretory functions on the ipsilateral and contralateral kidney in the cat.” Hypertension, 4:181-188 (1986). |
| Stouffer, G. A. et al., “Catheter-based renal denervation in the treatment of resistant hypertension.” Journal of Molecular and Cellular Cardiology, vol. 62, 2013, 6 pages. |
| Swartz, J. F., et al., “Radiofrequency endocardial catheter ablation of accessory atrioventricular pathway atrial insertion sites.” Circulation, 87: 487-499 (1993). |
| Uchida, F., et al., “Effect of radiofrequency catheter ablation on parasympathetic denervation: A comparison of three different ablation sites.” PACE, 21:2517-2521 (1998). |
| Verloop, W. L. et al., “Renal denervation: a new treatment option in resistant arterial hypertension.” Neth Heart J., Nov. 30, 2012, 6 pages, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547427/>. |
| Weinstock, M., et al., “Renal denervation prevents sodium retention and hypertension in salt sensitive rabbits with genetic baroreflex impairment.” Clinical Science, 90:287-293 (1996). |
| Wilcox, Josiah N., Scientific Basis Behind Renal Denervation for the Control of Hypertension, ICI 2012, Dec. 5-6, 2012. 38 pages. |
| Worthley, Stephen et al., “Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.” European Heart Journal, vol. 34, 2013, 9 pages. |
| Worthley, Stephen, “The St. Jude Renal Denervation System Technology and Clinical Review.” The University of Adelaide Australia, 2012, 24 pages. |
| Zuern, Christine S., “Impaired Cardiac Baroflex Sensitivity Predicts Response to Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Journal of the American College of Cardiology, 2013, doi: 10.1016/j.jacc.2013.07.046, 24 pages. |
| Miller, Reed, “Finding A Future For Renal Denervation With Better Controlled Trials.” Pharma & Medtech Business Intelligence, Article #01141006003, Oct. 6, 2014, 4 pages. |
| Papademetriou, Vasilios, “Renal Denervation and Symplicity HTN-3: “Dubium Sapientiae Initium” (Doubt Is the Beginning of Wisdom)”, Circulation Research, 2014; 115: 211-214. |
| Papademetriou, Vasilios et al., “Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions.” Circulation. 2014; 129: 1440-1450. |
| Papademetriou, Vasilios et al., “Catheter-Based Renal Denervation for Resistant Hypertension: 12-Month Results of the EnligHTN I First-in-Human Study Using a Multielectrode Ablation System.” Hypertension. 2014; 64: 565-572. |
| Doumas, Michael et al., “Renal Nerve Ablation for Resistant Hypertension: The Dust Has Not Yet Settled.” The Journal of Clinical Hypertension. 2014; vol. 16, No. 6, 2 pages. |
| Messerli, Franz H. et al. “Renal Denervation for Resistant Hypertension: Dead or Alive?” Healio: Cardiology today's Intervention, May/Jun. 2014, 2 pages. |
| Chinushi et al., “Blood Pressure and Autonomic Responses to Electrical Stimulation of the Renal Arterial Nerves Before and After Abiation of the Renal Artery.” Hypertension, 2013, 61, pp. 450-456. |
| Pokushalov et al., “A Randomized Comparison of Pulmonary Vein Isolation With Versus Without Concomitant Renal Artery Denervation in Patients With Refractory Symptomatic Atrial Fibrillation and Resistant Hypertension.” Journal of the American College of Cardiology, 2012, 8 pages. |
| International Searching Authority, International Search Report and Written Opinion dated Feb. 12, 2018 for PCT Application No. PCT/US2017/058731, 19 pages. |
| Böhm M, Mahfoud F, Ukena C, Hoppe UC, Narkiewicz K, Negoita M, Ruilope L, Schlaich MP, Schmieder RE, Whitbourn R, Williams B, Zeymer U, Zirlik A, Mancia G; “GSR Investigators First report of the Global SYMPLICITY Registry on the effect of renal artery denervation in patients with uncontrolled hypertension.” Hypertension. Apr. 2015;65(4):766-74. |
| Soulis JV1, Fytanidis DK1, Seralidou KV1, Giannoglou GD2, “Wall shear stress oscillation and its gradient in the normal left coronary artery tree bifurcations” HIPPOKRATIA 2014, 18, 1: 12-16. |
| Knight et al., “Choosing the optimal wall shear parameter for the prediction of plaque location—A patient-specific computational study in human right coromary arteries.” Elsevier Inc., Aug. 2010, vol. 211, Issue 2, pp. 445-450. |
| First Office Action and Search Report, and translation thereof, from counterpart Chinese Application No. 201780081286.2, dated Aug. 2, 2021, 20 pp. |
| Number | Date | Country | |
|---|---|---|---|
| 20190223956 A1 | Jul 2019 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15337742 | Oct 2016 | US |
| Child | 16262497 | US |
